

# Vaccines and Global Health: The Week in Review 12 April 2025 :: Issue 793 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <a href="https://centerforvaccineethicsandpolicy.net">https://centerforvaccineethicsandpolicy.net</a>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

**Request email delivery of the pdf:** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

**Support this knowledge-sharing service:** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

# Milestones, Perspectives

# <u>Countries are already experiencing significant health system disruptions – WHO</u>

10 April 2025 News release [Editor's text bolding]

The World Health Organization (WHO) issues warning on health service disruptions reported in 70% of its surveyed country offices as a result of sudden suspensions and reductions in official development assistance (ODA) for health.

The findings, based on rapid WHO assessment of the fast-evolving situation, raise concern for potentially deeper and prolonged effects on health systems and services across the world, especially in vulnerable and fragile settings. This requires urgent action and international response.

The new rapid stock take conducted in March–April 2025 with 108 WHO country offices, primarily in low- and lower-middle-income countries, shows that many countries are working to increase or reallocate funding from domestic and alternative external sources to address gaps. However, up to 24% of WHO Country Office responses suggest budget cuts are already translating into increased out-of-pocket payments. The poor and vulnerable likely risk bearing the additional brunt of these impacts.

"These results paint a worrying picture about the impact of the sudden and unplanned cuts to aid on the health of millions of people," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "Although these cuts are a shock, they are also driving an accelerated transition away from aid dependency to a more sustainable self-reliance, based on domestic resources. Many countries are asking for WHO's support, and WHO is working with them to identify and tailor the most effective measures."

The stock take reports provide an early snapshot and insights from WHO country offices that work closely with ministries of health, providing regular support on health systems policies and planning. The stock take aimed at identifying the urgent support countries need to avoid catastrophic impacts on the health of the populations and to guide monitoring of the rapidly evolving situation.

# Key findings from the stock take show the following.

- :: The suspensions and reductions in ODA are disrupting all health system functions, with the most frequently reported impacts being on health emergency preparedness and response (70%), public health surveillance (66%), service provision (58%), humanitarian aid (56%), and the health and care workforce (54%).
- :: Health services are being disrupted across the board in at least one third of the responding countries, with high levels of disruptions reported in outbreak detection and response, malaria, HIV, tuberculosis, sexually transmitted infections, family planning, and maternal and child health services.

The nature and scale of service disruptions are comparable to those observed during the peak periods of the COVID-19 pandemic in some settings.

- :: Critical shortages in the availability of medicines and health products are leaving one third of responding countries without commodities for major service areas.
- :: The pause in ODA has led to job losses for health and care workers in over half of responding countries, and significant disruptions to trainings.
- :: **Information systems are particularly impacted as key health data collection is disrupted**. Over 40% of countries experienced disruptions to key information systems, including collaborative surveillance and emergency systems, health management information systems, disease-specific reporting systems, lab information systems, and household/population surveys.

:: **Eighty-one of the 108 WHO country offices have expressed the need for support** across a broad range of health areas, including innovative funding and resource mobilization, targeted technical assistance and support.

Given the rapidly evolving context, WHO will be monitoring the situation over time and will engage the global health community, including partners and donor agencies, to **inform urgent response plans** to mitigate deepening country impacts and enable greater sustainability.

#### Note to editors:

These findings represent a snapshot of the health systems and health services situation in the context of a rapidly evolving situation. Senior WHO country office staff were surveyed over the period of 7 March to 2 April 2025 to provide inputs and observations on the impact of ODA suspensions and reductions through a structured survey. WHO country offices in low- and lower-middle-income countries across all six WHO regions were included in this survey. They do not reflect the official views of the governments in the countries, territories and areas. WHO has a global presence in 150+ locations putting central focus on countries and populations, working to protect and improve the health of everyone, everywhere. More information.

::::::::

#### **Pandemic Accord**

# A/INB/13 (Resumed session and drafting group)

Intergovernmental Negotiating Body **7-11 April 2025** A/INB/13/2 Rev.2 - Draft programme of work

No announcements or status update identified on the INB page.

**Reuters,** April 12, 20255:56 AM EDT Updated 13 hours ago WHO members close to accord on tackling future pandemics, sources say

By <u>Emma Farge</u>, <u>Olivia Le Poidevin</u> and <u>Rajveer Pardesi</u> *Summary* 

- :: Agreement near after overnight negotiations, sources close to process say, next session on Tuesday
- :: Treaty aims to improve global defences against pathogens
- :: Contentious issues include fair distribution of vaccines and drugs GENEVA, April 12 (Reuters) Members of the World Health

Organization are close to a deal on a treaty to prepare for future pandemics, sources involved in the talks told Reuters on Saturday, with a WHO spokesperson saying discussions had been paused until Tuesday...

::::::::

IFPMA - Statement

# 13th Resumed meeting of the Intergovernmental Negotiating Body (INB)

On 7 April in Geneva, IFPMA delivered a statement at the 13th resumed meeting of the INB to agree a WHO instrument for pandemic prevention, preparedness, and response.

The biopharmaceutical industry is pivotal in preparing for and responding to pandemics, driving the innovation necessary to develop pharmaceuticals and other critical products for future health crises.

To enhance pandemic preparedness and response, it is essential to focus on sustaining scientific research on pathogens with pandemic potential while ensuring equitable access to vaccines and treatments during a pandemic emergency. This goal can only be achieved through a strong intellectual property system that must be protected.

As stated in the <u>Berlin Declaration</u> and <u>Equitable Access</u> statements, the industry is dedicated to broadening access to its products during pandemic emergencies through various strategies, including donations, equity-based tiered pricing, voluntary licensing, and voluntary technology transfers on mutually agreed terms. The significance of including both "voluntary" and "on mutually agreed terms" for technology transfer is paramount, as it facilitates the sharing of technologies and expertise in a manner that respects the interests and agreements of all parties involved.

Different situations and countries may require diverse interventions at various stages of a pandemic emergency. Therefore, it is crucial to establish a flexible system that allows a wide range of companies to utilize their skills and expertise effectively.

To promote equitable access, we urge Member States to implement measures both before and during a pandemic to support healthcare systems, enhance surveillance mechanisms, streamline regulatory procedures, develop accurate forecasts, and ensure that companies receive the necessary orders to scale up production. By addressing these barriers, Member States can help ensure that life-saving innovations reach those in need. This preparedness and response system must function effectively at global, regional, and national levels.

We remain committed to sharing our knowledge and providing our expertise to support global health initiatives and strengthen pandemic preparedness and response.

.....

#### Gavi

# <u>Testimony :: US House Committee on Appropriations</u> - <u>Sania Nishtar, CEO Gavi, the Vaccine</u> Alliance,

LinkedIn Post 10 April, 2025

Gavi's work not only benefits global health but also directly supports US interests by making America safer, stronger, and more prosperous. My thanks to the US House Committee on Appropriations for the opportunity to provide testimony on how <u>Gavi</u>, the <u>Vaccine Alliance</u> strengthens the world's ability to protect itself against outbreaks and health emergencies. Watch my testimony <u>here</u>:

::::::::

### Polio - PHEIC

# Polio this week - 09 April 2025

#### Headlines

:: Poliovirus-essential facility (PEF) in Belgium awarded world's first Certificate of Containment — a polio vaccine manufacturing facility in Belgium became the first ever PEF to receive a full Certificate of Containment (CC), approved by the Global Commission for the Certification of Eradication of Poliomyelitis (GCC). This work is part of ongoing worldwide efforts to ensure the safe and secure containment of polioviruses in facilities that retain them. More.

:: Advance notification was received this week of a cVDPV2 isolated from an environmental sample in Papua New Guinea. The virus was isolated only from the environment – no associated cases of paralysis have been detected...

# Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: 19 WPV1-positive environmental samples
- Algeria: two cVDPV2-positive environmental samples
- Chad: two cVDPV2 cases and one cVDPV2-positive environmental sample
- Nigeria: two cVDPV2-positive environmental samples
- Senegal: one cVDPV2-positive environmental sample

::::::::

#### **Statement of the forty-first meeting of the Polio IHR Emergency Committee**

10 April 2025 Statement Geneva

[Excerpts; Editor's text bolding]

The 41<sup>st</sup> meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on the international spread of poliovirus was convened by the WHO Director-General on 6 March 2025 with committee members and advisers meeting via video conference with affected countries, supported by the WHO Secretariat.

The Emergency Committee reviewed the data on wild poliovirus (WPV1) and circulating vaccine derived polioviruses (cVDPV) in the context of the global target of interruption and certification of WPV1 eradication by 2027 and interruption and certification of cVDPV2 elimination by 2029. Technical updates were received about the situation in the following countries: Afghanistan, Algeria, Chad, Democratic Republic of the Congo (DR Congo), Djibouti, Ethiopia, Germany, Pakistan, Poland and the United Kingdom of Great Britain and Northern Ireland...

#### ...Conclusion

The Committee unanimously agreed that the risk of international spread of poliovirus continues to constitute a Public Health Emergency of International Concern (PHEIC) and recommended extending the Temporary Recommendations for a further three months. In reaching this conclusion, the Committee considered the following factors:

#### Ongoing risk of WPV1 international spread:

Based on the following factors, there remains the risk of international spread of WPV1:

- Intensifying WPV1 transmission with geographical spread into formerly endemic areas and core reservoirs of Afghanistan (South) and Pakistan (Karachi, Peshawar, Quetta Block) as well as other epidemiologically critical areas like Central Pakistan, and parts of Punjab province in Pakistan that were without any WPV1 detection for prolonged periods of time.
- That WPV1 transmission has been re-established in the south region of Afghanistan and Karachi, and Quetta Block of Pakistan.
- This intensifying WPV1 transmission in both endemic countries during the low transmission season indicates sizeable cohort of unimmunized and under-immunized children.
- Lack of house-to-house vaccination campaigns in Afghanistan represents a major risk of further WPV1 spread and intensification of its transmission.
- Certain geographies and population pockets in the epidemiologically critical areas of Pakistan continue to have inconsistent campaign quality and substantial number of unimmunized and under-immunized children due to insecurity, operational gaps, and vaccine hesitancy.
- Ongoing population movement between the two endemic countries, including the returnees from Pakistan to Afghanistan, leading to cross-border WPV1 transmission.

 Ongoing population movement from the two endemic countries to other countries, neighbouring and distant.

**Ongoing risk of cVDPV international spread:** 

Based on the following factors, the risk of international spread of cVDPV appears to remain high:

- Ongoing cross border spread including into newly re-infected countries and territories.
- Continued cVDPV2 transmission in the critical areas of Nigeria, with 36% of the global cVDPV2 cases in 2024 and its potential to amplify the transmission.
- The cVDPV2 transmission in the Horn of Africa seems to be intensifying, particularly in Ethiopia.
   The Horn of Africa countries continue to face humanitarian and health emergencies making it challenging to implement high-quality vaccination campaigns in a timely manner.
- There is a large pool of unimmunized susceptible children in the Northern Governorates of Yemen. There are challenges regarding timely shipping of AFP stool specimens from northern Yemen.
- The widening gap in population intestinal mucosal immunity in young children since the withdrawal of OPV2 in 2016, as well as high concentration of zero dose children in certain areas.
- Despite the decreasing number of cVDPV1 cases, a new emergence was detected in DR Congo in 2024, indicating a population immunity gap.
- Resurgence of cVDPV3 after more than two years, infecting French Guiana and Guinea.

# Contributing factors include:

- Sub-optimal routine immunization: Many countries have weak immunization systems that can be further impacted by humanitarian emergencies including conflict and protracted complex emergencies. This poses a growing risk, leaving populations in these fragile states vulnerable to polio outbreaks.
- Ongoing insecurity and conflict in many areas that are the source of cVDPV transmission.
- Lack of access: Inaccessibility continues to be a major risk, particularly in northern Yemen and Somalia which have sizable populations that have been unreached with polio vaccine for extended periods of more than a year.
- The current resource-constrained environment further challenges the full and effective implementation of critical eradication activities...

#### Additional considerations

The Committee noted that the Global Polio Eradication Initiative needs to reconsider its priorities and reprogram its operations in response to the current fiscal constraints. The current financial shortfall poses a significant risk to eradication efforts. The Committee acknowledges and appreciates the Kingdom of Saudi Arabia's recent confirmation of its \$500 million commitment to global polio eradication. The committee urged donor countries and organizations to enhance their financial support, emphasizing that failure is not an option. The Committee also called on national governments to prioritize polio eradication in their domestic funding allocations to ensure sustained progress toward eradication.

The Committee expressed deep concern over the escalating and expanding WPV1 transmission in Afghanistan and Pakistan. The persistence of WPV1 transmission despite ongoing vaccination campaigns highlights gaps in immunization quality. The Committee also noted that the current levels of WPV1 transmission during the low season could further intensify during the high transmission season if uniform, high-quality campaigns, particularly in core reservoir areas, are not ensured.

The Committee remains concerned about the continued inability to conduct house-to-house vaccination campaigns in Afghanistan. This challenge places infants and young children,

particularly girls, at a heightened risk of missing polio vaccination. The Committee appreciates the efforts to improve women's participation in site-to-site polio vaccination as well as for border vaccination and encourages to expand these efforts to high-risk South Region of Afghanistan.

The Committee acknowledged the strong political commitment to polio eradication in Afghanistan and Pakistan. The Committee emphasized that this commitment must translate into concrete operational actions to strengthen community engagement and implement high-quality vaccination campaigns. These efforts are essential to interrupt the ongoing intense WPV1 transmission and mitigate the risk of national and international spread. In Afghanistan. The Committee specifically recommended the resumption of house-to-house vaccination campaigns and the recruitment of additional female vaccinators to enhance community acceptance and improve coverage.

The Committee is encouraged by the improving cVDPV1 situation in the African Region, particularly in Madagascar, which has not reported any cases for over 16 months. The Committee emphasized the need to sustain high-quality vaccination efforts, particularly in the DR Congo and Mozambique, the only two countries that have reported cVDPV1 cases in 2024.

The Committee noted the ongoing transmission of cVDPV2 in the African Region, particularly in northern Nigeria. While there has been an overall decline in cVDPV2 cases in 2024, the Committee expressed concern over the increase in cases reported by Angola, Ethiopia, Niger, Nigeria, South Sudan, and Yemen compared to 2023. The Committee also noted the concerning cVDPV2 epidemiological situation in Chad and Algeria and recommended the implementation of high-quality vaccination campaigns to boost population immunity. The Committee noted the challenges in implementing high-quality immunization responses in critical areas of the African Region and northern Yemen. Additionally, the Committee expressed concerns over surveillance gaps in northern Yemen, which may further hinder early detection and response efforts.

The Committee noted the detection of cVDPV3 in Guinea and French Guiana in 2024, after more than two years with no reported detections globally and emphasized the need for a high-quality surveillance and immunization response to contain these outbreaks.

The Committee noted that several cVDPV-affected countries continue to face conflict and insecurity, which disrupts both routine immunization and polio vaccination campaigns. The Committee also noted that ongoing health emergencies and disease outbreaks in several countries further complicate the timely and effective implementation of polio vaccination campaigns. Given the diverse challenges across countries and sub-national areas, the Committee emphasized the need for context-specific, tailored interventions to ensure high-quality campaigns and ultimately stop cVDPV outbreaks. The Committee also underscored the importance of synchronized sub-regional approaches and strong cross-border coordination to address challenges related to permeable borders and shared operational constraints across affected countries.

The Committee noted some good practices in several countries, particularly in cross-border collaboration and surveillance. The Committee encourages countries to document and share these best practices and suggests that GPEI facilitates this process.

The Committee noted the ongoing cross-border spread of cVDPV2 in the African and Eastern Mediterranean Regions, as well as the recent detection of cVDPV2 in five countries of the European Region. This reinforces that polio remains a global risk until it is fully eradicated. The Committee acknowledged the ongoing response efforts of Finland, Germany, Poland, Spain, and the United Kingdom of Great Britain and Northern Ireland in strengthening surveillance and addressing subnational immunity gaps. The Committee also appreciated the inter-country coordination in the European Region, facilitated by the WHO European Regional Office, in response to the cVDPV2

detections in the region. The Committee recommended continued surveillance strengthening across the European Region, along with regular risk assessments to ensure timely identification and mitigation of emerging polio risks.

The Committee highlighted the importance of maintaining sensitive surveillance in polio-infected and high-risk countries and recommended that GPEI provide all possible support under the Global Polio Surveillance Action Plan. The Committee also underscored the importance of high-income countries maintaining high-quality surveillance for polioviruses, given the ongoing risk of importation, as recently demonstrated by cVDPV detections in the European Region. Robust surveillance remains essential for early detection and timely response to importations and newly emerging outbreaks.

The Committee noted that novel OPV2 continues to demonstrate greater genetic stability compared to Sabin OPV2. However, the risk of new cVDPV2 emergences increases when the interval between outbreak response campaigns exceeds four weeks or when vaccination quality is suboptimal, underscoring the need for timely and high-quality immunization efforts.

The Committee noted that the amendments to the International Health Regulations (2005) (IHR) through resolution WHA77.17 (2024), were notified to States Parties on 19 September 2024 and that they would come into effect on 19 September 2025 for 192 States Parties. Regarding any potential effects of these amendments on the Committee, the Secretariat informed the Committee that it would be premature to assess any such effects at this time but would brief the Committee ahead of their entry into force in September 2025, should the Committee continue to be convened under the IHR at this time.

Based on the current situation regarding WPV1 and cVDPVs, and the reports provided by affected countries, the Director-General accepted the Committee's assessment, and on 09 April 2025 determined that the poliovirus situation continues to constitute a Public Health Emergency of International Concern (PHEIC) with respect to WPV1 and cVDPV. The Director-General endorsed the Committee's recommendations for countries meeting the definition for 'States infected with WPV1, cVDPV1 or cVDPV3 with potential risk for international spread', 'States infected with cVDPV2 with potential risk for international spread' and for 'States previously infected by WPV1 or cVDPV within the last 24 months' and extended the Temporary Recommendations under the IHR to reduce the risk of the international spread of poliovirus, effective, 9 April 2025.

.....

#### mPox - PHEIC

# Multi-country outbreak of mpox, External situation report #50 - 11 April 2025

Clade Ib monkeypox virus (MPXV) cases continue to be reported in the African Region, where nine countries have community transmission of this strain, as well as in countries outside of Africa among travelers returning from affected countries.

# ...5. Access to and delivery of countermeasures Access and Allocation Mechanism (AAM) Vaccines

:: WHO continues to provide technical support to accelerate implementation and uptake of mpox vaccination in affected countries for people at risk, in support of controlling the surge in mpox cases on the African continent.

- :: To date, 1 001 480 vaccine doses have been delivered to nine countries, including 50 000 doses of LC16m8 vaccine from Japan to the Democratic Republic of the Congo in January 2025.
- :: Vaccination activities have started in six countries (the Central African Republic, Democratic Republic of the Congo, Nigeria, Rwanda, Sierra Leone and Uganda) while The United Republic of Tanzania, and Zambia are preparing national mpox vaccine deployment plans and are likely to submit vaccine dose requests to the AAM soon.
- :: Bavarian Nordic's position on product liability: When national regulatory authorities allow age indications which are not on the label of the product (e.g. one year and above, or 12 years and above) in the Marketing Authorization (MA) or Emergency Use Authorization (EUA), Bavarian Nordic covers the product liability as per the indicated authorized age groups.
- :: The Democratic Republic of the Congo and Japan resumed discussions last week on the shipment of the remaining doses of LC16m8 vaccine to the country which had been put on hold following a period of insecurity.
- :: The AAM partners continue to work together to ensure countries receive guidance to get operational funds for implementation of the national vaccination plans.

KEY FIGURES				
Reporting period: 1 Januar	ry 2022 – 28 Februa	ry 2025		
Area	Number of reported confirmed cases		Number of deaths among confirmed cases	Number of reporting countries
Global	133 018		293¹	131
Reporting period: 1 Januar	ry 2024 – 30 March :	2025		
Area	Number of reported confirmed cases		Number of deaths among confirmed cases	
	2024	2025	2024	2025
Africa	19 733	8647	52	49
Democratic Republic of the Congo <sup>2</sup>	14 789	3924	29³	18
Uganda	1353	3528	12	25
Burundi	2946	779	1	0
Reporting period: last six	weeks, 17 February	- 30 March 2025		
Africa	3339		26	
Democratic Republic of the Congo	1083		12	
Uganda	1753		10	
Burundi	258		0	

#### **GenAI – Health and Medicine**

::::::::

<u>Generative Artificial Intelligence in Health and Medicine: Opportunities and Responsibilities for Transformative Innovation</u>

A Special Publication from the National Academy of Medicine

The National Academies Press. https://doi.org/10.17226/28907.

PDF: The National Academies Press. https://doi.org/10.17226/28907.

The integration of large language models (LLMs) and generative artificial intelligence (AI) in health care holds the potential to transform the practice of medicine, the work and experiences of health care providers, and the health and well-being of patients. Generative AI can support clinical decision making

and streamline workflows, promote patients and their support networks' engagement in care processes, and support clinical research.

However, successful and ethical implementation of generative AI requires careful consideration of the associated risks, particularly those concerning data privacy, bias, transparency, and infrastructure limitations.

Generative Artificial Intelligence in Health and Medicine: Opportunities and Responsibilities for Transformative Innovation explores the transformative potential of generative AI in health care, with a focus on its applications in clinical decision making, administrative efficiency, and patient engagement.

:::::::

**Science: Integrity** 

# Some 1,900 scientists accuse Trump of 'wholesale assault' on science

Washington Post, Updated April 3, 2025

In a letter, several members of the National Academies of Sciences, Engineering, and Medicine warn Trump's overhaul of U.S. science has created a "climate of fear."...

:::::::

#### **TO THE AMERICAN PEOPLE**

We all rely on science. Science gave us the smartphones in our pockets, the navigation systems in our cars, and life-saving medical care. We count on engineers when we drive across bridges and fly in airplanes. Businesses and farmers rely on science and engineering for product innovation, technological advances, and weather forecasting. Science helps humanity protect the planet and keeps pollutants and toxins out of our air, water, and food.

For over 80 years, wise investments by the US government have built up the nation's research enterprise, making it the envy of the world. **Astoundingly, the Trump administration is destabilizing this enterprise by gutting funding for research, firing thousands of scientists, removing public access to scientific data, and pressuring researchers to alter or abandon their work on ideological grounds.** 

The undersigned are elected members of the National Academies of Sciences, Engineering, and Medicine, representing some of the nation's top scientists, engineers, and medical researchers. We are speaking out as individuals. We see real danger in this moment. We hold diverse political beliefs, but we are united as researchers in wanting to protect independent scientific inquiry. We are sending this SOS to sound a clear warning: the nation's scientific enterprise is being decimated...

[full text at title link above]

::::::::

### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

:::::::

### WHO & Regional Offices [to 12 Apr 2025]

https://www.who.int/news

Selected News/Announcements/Statements

10 April 2025 News release

Countries are already experiencing significant health system disruptions – WHO

10 April 2025 Statement

Statement of the forty-first meeting of the Polio IHR Emergency Committee

10 April 2025 News release

WHO launches first-ever guidelines on meningitis diagnosis, treatment and care

7 April 2025 Statement

World must act with urgency to save Palestinians in Gaza

7 April 2025 *Joint News Release* 

Aid cuts threaten fragile progress in ending maternal deaths, UN agencies warn

::::::

# **WHO Regional Offices**

Selected Press Releases, Announcements

# **WHO African Region AFRO**

:: 11 April 2025

Angola takes measures to improve access to safe water and curb cholera

::10 April 2025

**Congo: Innovative tools to reduce maternal mortality** 

:: 09 April 2025

Africa faces critical shortage of oral health workers amid rising disease burden

#### **WHO Region of the Americas PAHO**

:: 7 Apr 2025

# <u>PAHO highlights progress in reducing maternal mortality in the Americas, but warns of persistent challenges</u>

Washington D.C., April 7, 2025 (PAHO) – On World Health Day 2025, the Pan American Health Organization (PAHO) has warned that while the region of the Americas has progressed towards reducing maternal mortality, challenges remain, requiring urgent efforts to ensure all women have access to quality maternal health care. According to the United...

:: 7 Apr 2025

# <u>South America nears eradication of foot-and-mouth disease, with over 65% of livestock in disease-free zones without vaccination</u>

Santa Cruz de la Sierra, April 7, 2025 (PANAFTOSA - PAHO) – Two out of three cattle in South America are currently located in foot-and-mouth disease (FMD)-free zones where vaccination is not practiced. Across the entire Americas, more than 80% of cattle are in this condition, bringing the region closer to the eradication of the disease. This...

#### **WHO South-East Asia Region SEARO**

No new digest content identified.

# **WHO European Region EURO**

:: 10 April 2025 News release

"Poliovirus-essential" facility in Belgium awarded world's first Certificate of Containment

:: 9 April 2025 News release

WHO announces new collaborating centre on digital health in Germany

:: 7 April 2025 Media release

**Achieving a TB-free Central Asia: from vision to reality** 

# WHO Eastern Mediterranean Region EMRO

:: Fatima: crossing deserts to protect mothers and newborns in Pakistan

3 April 2025

:: Improving health care for Afghan refugees and host communities in Pakistan

2 April 2025

# **WHO Western Pacific Region**

No new digest content identified.

::::::

# **WHO - Emergency situation reports**

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

Multi-country outbreak of mpox, External situation report #50 - 11 April 2025

::::::

# <u>Disease Outbreak News (DONs)</u>

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

# 11 April 2025 | Invasive meningococcal disease - Kingdom of Saudi Arabia

Situation at a glance

On 13 March 2025, the International Health Regulations (IHR) National Focal Point (NFP) for the Kingdom of Saudi Arabia (KSA) reported 11 cases of invasive meningococcal disease (IMD) to WHO. Additionally, between 11 February and 18 March 2025, the WHO Eastern Mediterranean Regional IHR contact point received reports of six isolated cases of IMD, either through notification or bilateral communication with IHR NFPs. These cases involve individuals who had recently returned from Umrah. Meningococcal disease remains a global public health concern, particularly in the context of mass gathering events such as Hajj and Umrah. The government of Saudi Arabia regularly issues health requirements for Hajj and Umrah, including vaccination policies. As of 10 March 2025, KSA health authorities estimated that only 54% of international Umrah pilgrims had complied with the meningococcal vaccination requirements. The significant number of pilgrims traveling to KSA from countries with varying levels of meningococcal disease incidence presents a risk of international spread during these gatherings. Given the recent notification of these cases linked to Umrah, WHO strongly advises all individuals planning to attend mass gatherings such as Hajj and Umrah to receive vaccination against meningococcal disease at least 10 days prior to travel.

::::::

# **Weekly Epidemiological Record**

Vol. 100, Nos. 15, pp. 123-130 11 April 2025

https://www.who.int/publications/journals/weekly-epidemiological-record

:: WHO's Health Emergencies Programme: acute emergencies monthly summary – February–March 2025

::::::

#### **New WHO Publications**

https://www.who.int/publications

Selected

11 April 2025

Mass gathering practical guide for simulation exercises and after action reviews

10 April 2025

WHO guidelines on meningitis diagnosis, treatment and care

9 April 2025

WHO SEAR 7th Epidemiological Bulletin 2025

8 April 2025

Social listening in infodemic management for public health emergencies: guidance on ethical considerations

7 April 2025

<u>Trends in maternal mortality 2000 to 2023: estimates by WHO, UNICEF, UNFPA, World Bank Group and UNDESA/Population...</u>

::::::

#### **USA - HHS, FDA, CDC+**

#### Editor's Note:

We employ bolded red text below to identify observations we assess might be useful to readers.

#### HHS

News

No new digest content identified on website.

#### **BBC News**

#### RFK Jr pledges to find the cause of autism by September

11 April 2025, Mike Wendling

US Health Secretary Robert F Kennedy Jr has pledged "a massive testing and research effort" to determine the cause of autism in five months.

Experts cautioned that finding the causes of autism spectrum disorder – a complex syndrome that has been studied for decades – will not be straightforward, and called the effort misguided and unrealistic.

Kennedy, who has promoted debunked theories suggesting autism is linked to vaccines, said during a cabinet meeting on Thursday that a US research effort will "involve hundreds of scientists from around the world."

"By September, we will know what has caused the autism epidemic and we'll be able to eliminate those exposures," Kennedy said...

NIH [to 12 Apr 2025] http://www.nih.gov/ News Releases No new digest content identified.

#### **FDA**

Press Announcements

<u>April 10, 2025 - FDA Announces Plan to Phase Out Animal Testing Requirement for</u> Monoclonal Antibodies and Other Drugs

... The FDA's animal testing requirement will be reduced, refined, or potentially replaced using a range of approaches, including AI-based computational models of toxicity and cell lines and organoid toxicity testing in a laboratory setting (so-called New Approach Methodologies or NAMs data). Implementation of the regimen will begin immediately for investigational new drug (IND) applications, where inclusion of NAMs data is encouraged, and is <u>outlined in a roadmap</u> also being released today. To make determinations of efficacy, the agency will also begin use pre-existing, real-world safety data from other countries, with comparable regulatory standards, where the drug has already been studied in humans...

#### **FDA VRBPAC**

Advisory Committee Calendar

The Advisory Committee calendar does not list any future scheduled meetings of VRBPAC.

<u>One other advisory committee</u> meeting has been added to the overall calendar in the last week.

**CDC/ACIP [U.S.]** [to 12 Apr 2025]

http://www.cdc.gov/media/index.html

Latest News

**CDC Statement on Measles Outbreak** 

CDC is aware of the second measles death in Texas, and our thoughts are with the family. Apr 7, 2025

Secretary Kennedy's directive is for CDC to lead the nation in health readiness and response. His <u>visit</u> <u>to Texas</u>, to support the state's efforts to control the measles outbreak, resulted in discussions with Texas state health officials to deploy another CDC response team to the area to further assist with the state's efforts to protect its citizens against measles and its complications.

### **ACIP Meetings** [to 12 Apr 2025]

Next ACIP Meetings

:: April 15-16

Final ACIP April 15-16, 2025 Meeting Agenda (posted 4-11-2025)

Draft ACIP April 15-16, 2025 Meeting Agenda (posted 3-24-2025)

Previous ACIP Feb. 26-28, 2025 Meeting Agenda (rescheduled, posted 1-17-2025)

:: June 25-26 :: October 22-23

#### **National Vaccine Program**

https://www.hhs.gov/vaccines/about/index.html Upcoming Meetings/Latest Updates No 2025 meeting dates posted.

#### **MMWR Weekly**

https://www.cdc.gov/mmwr/index2025.html

# April 10, 2025 / No. 12

PDF of this issue

No new digest content identified.

::::::

### **Europe**

# **European Centre for Disease Prevention and Control**

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

Surveillance and monitoring

# Communicable disease threats report, 5 - 11 April 2025, week 15

11 Apr 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 5 - 11 April 2025 and includes updates on Middle East respiratory syndrome coronavirus (MERS-CoV), Influenza A(H5N1), chikungunya, Ebola and an overview of respiratory virus epidemiology in the EU/EEA. Assessment

Surveillance and monitoring

# Survey on testing strategies for HIV in blood, tissues and cell donors within the EU/EEA 9 Apr 2025

Report on the findings of a survey on testing strategies for HIV in blood, tissues and cell donors within the EU/EEA at the time of development of ECDC guidelines for the prevention of donor-derived transmission of human immunodeficiency virus (HIV) through SoHO.

# **European Medicines Agency [EMA]**

https://www.ema.europa.eu/en/news

News & Press Releases

# <u>Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10</u> <u>April 2025</u>

PRAC carried out its broad range of responsibilities for managing the risks associated with medicine use 11 April 2025

::::::

#### Africa CDC [to 12 Apr 2025]

https://africacdc.org/

Press Releases, Statements [Selected]

Press Releases

# Africa CDC Unveils Strategic Plan to Transform Health Financing and Advance Self-Reliance 11 April 2025

... "Africa cannot continue outsourcing its health security," said Dr. Jean Kaseya, Director General of Africa CDC. "This strategy is not about aid—it's about ownership. We are building a future where Africa invests in its people, drives its own health agenda, and responds to crises with speed, strength, and self-reliance."

The strategy urges governments to fulfil the Abuja Declaration by allocating at least 15% of national budgets to health. It also introduces innovative financing ideas such as solidarity levies on airline tickets, alcohol, and mobile services, while exploring how Africa's US\$95 billion in annual diaspora remittances can support national health priorities. Blended finance tools will be used to unlock public

and private capital for critical investments in infrastructure, digital health, and local production of vaccines and medical supplies.

Implementation will be phased. The first phase (2025–2026) will focus on updating national health financing plans in 30 countries, piloting innovative revenue mechanisms, and launching transparency dashboards. The second phase (2026–2030) will scale successful approaches, with the goal of enabling at least 20 countries to finance 50 percent or more of their health budgets through sustainable domestic sources.

To track results and ensure accountability, Africa CDC will deploy a new African Health Financing Scorecard to monitor progress, improve donor alignment, and boost efficiency in domestic spending...

Stories

# Africa's Plan to Fill Health Funding Gaps Amidst Declining Coffers

11 April 2025

Stories

#### **Health Workforce Plight in Africa**

11 April 2025

Stories

# **Getting to Know the Regional Capacity and Capability Network for North Africa**

10 April 2025

Stories

# **Africa CDC Supports Angola to Fight Cholera**

10 April 2025

Stories

# **Planning for Outbreak Response Readiness**

10 April 2025

::::::

#### China CDC+

http://www.chinacdc.cn/en/

# **National Health Commission of the People's Republic of China** [to 12 Apr 2025]

http://en.nhc.gov.cn/

News

No new digest content identified.

#### National Medical Products Administration – PRC [to 12 Apr 2025]

http://english.nmpa.gov.cn/

News

No new digest content identified.

**China CDC** 

# **CCDC Weekly Reports: Current Volume (7)**

2025-04-11 / No. 15

PDF of this issue

No new digest content identified.

::::::

#### ::::::

# Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

# **Organization Announcements**

# **Paul G. Allen Frontiers Group** [to 12 Apr 2025]

https://alleninstitute.org/news-press/

News

# Scientists complete largest wiring diagram and functional map of the brain to date

Apr 9, 2025

The MICrONS Project is considered the most complicated neuroscience experiment ever attempted

#### **BMGF - Gates Foundation** [to 12 Apr 2025]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements

No new digest content identified.

# **Bill & Melinda Gates Medical Research Institute** [to 12 Apr 2025]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications No new digest content identified.

#### **CARB-X** [to 12 Apr 2025]

https://carb-x.org/

News

No new digest content identified.

#### **Chan Zuckerberg Initiative** [to 12 Apr 2025]

https://chanzuckerberg.com/newsroom/

Newsroom

No new digest content identified.

# **CEPI – Coalition for Epidemic Preparedness Innovations** [to 12 Apr 2025]

http://cepi.net/

CEPI News, Blog No new digest content identified.

# CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 12

Apr 2025]

https://cioms.ch/

News; Publications; Events No new digest content identified.

# **DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 12 Apr 2025]

https://www.darpa.mil/news

News

No new digest content identified.

# **DNDI – Drugs for Neglected Diseases initiative** [to 12 Apr 2025]

https://dndi.org/press/press-releases/

Press Releases

No new digest content identified.

# **Duke Global Health Innovation Center** [to 12 Apr 2025]

https://dukeghic.org/

News

No new digest content identified.

#### **EDCTP** [to 12 Apr 2025]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials No new digest content identified.

#### **Emory Vaccine Center** [to 12 Apr 2025]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

#### **European Vaccine Initiative** [to 12 Apr 2025]

http://www.euvaccine.eu/

Latest News, Events

#### EVI initiates a new clinical trial to protect pregnant women against malaria

EVI launched Phase II clinical trial to evaluate the R21/Matrix-M malaria vaccine (by Univ. of Oxford), in women of

#### Fondation Merieux [to 12 Apr 2025]

http://www.fondation-merieux.org/

News, Events

Événement co-organisé par la Fondation Mérieux & l'Université de Genève

25ème Cours avancé de vaccinologie (ADVAC)

5-16 mai 2025 - Centre des Pensières, Veyrier-du-Lac (France)

Gavi [to 12 Apr 2025]

https://www.gavi.org/

Press Releases

7 April 2025

Gavi supports Côte d'Ivoire's largest HPV vaccination campaign targeting over 3 million girls

### **GE2P2 Global Foundation** [to 12 Apr 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review April 2025
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 20 Mar 2025
- :: Genomics :: Governance, Ethics, Policy, Practice A Monthly Digest March 2025

#### **GHIT Fund** [to 12 Apr 2025]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

### Global Fund [to 12 Apr 2025]

https://www.theglobalfund.org/en/news/

News Releases

No new digest content identified.

# **Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 12 Apr

2025]

https://www.glopid-r.org/news/

News

No new digest content identified.

#### **Hilleman Laboratories** [to 12 Apr 2025]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

#### **HHMI - Howard Hughes Medical Institute** [to 12 Apr 2025]

https://www.hhmi.org/news

#### Press Room

#### **David Liu Awarded Breakthrough Prize**

HHMI Investigator who developed groundbreaking gene-editing technologies among eight honored for transformative advances in the life sciences.

Apr 5, 2025

# **Human Immunome Project [nee Human Vaccines Project]** [to 12 Apr 2025]

https://www.humanimmunomeproject.org/

News

Website not responding at inquiry.

**IAVI** [to 12 Apr 2025] <a href="https://www.iavi.org/">https://www.iavi.org/</a> *Press Releases, Features*No new digest content identified.

**INSERM** [to 12 Apr 2025] https://www.inserm.fr/en/home/ Press Releases No new digest content identified.

# **International Coalition of Medicines Regulatory Authorities [ICMRA]**

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research No new digest content identified.

# ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 12 Apr 2025]

https://www.ich.org/

News/Pubs/Press Releases [Selective]

8 April 2025

# <u>ICH receives the Outstanding Contribution to Health Award at the DIA Europe meeting</u> March in Basel 2025

As ICH celebrates its 35th anniversary in 2025, DIA proudly honors its extraordinary impact on global health.

**ICRC** [to 12 Apr 2025]

https://www.icrc.org/en/whats-new

Latest press releases and statements [Selected]

Somalia: Frontline hospitals under pressure as fighting escalates

*News release* 10-04-2025

<u>Sudan: "We have nothing to go back to" – new report sheds light on two years of devastation in Sudan</u>

*News release* 10-04-2025

# Haiti: Renewed clashes fuel a humanitarian crisis that has no end in sight

Article 08-04-2025

**IFFIm** [to 12 Apr 2025]

http://www.iffim.org/

Press Releases/Announcements

"A wonderful development": in malaria-plagued northern Nigeria, the vaccine's arrival brings joy

07 Apr 2025

**IFRC** [to 12 Apr 2025]

http://media.ifrc.org/ifrc/news/press-releases/

Press releases

Myanmar relief operations intensify as IFRC coordinates complex supply chains

11/04/2025 | Press release

# **IPPS - International Pandemic Preparedness Secretariat** [to 12 Apr 2025]

https://ippsecretariat.org/news/

News

No new digest content identified.

# **Institut Pasteur** [to 12 Apr 2025]

https://www.pasteur.fr/en/press-area

Press Documents

No new digest content identified.

#### **ISC / International Science Council** [to 12 Apr 2025]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

No new digest content identified.

# **International Union of Immunological Societies (IUIS)**

https://iuis.org/

News/Events [Selected]

19th International Congress of Immunology

Vienna, August 17-22, 2025.

**IVAC** [to 12 Apr 2025]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [to 12 Apr 2025]
<a href="http://www.ivi.int/">http://www.ivi.int/</a>
IVI News & Announcements
No new digest content identified.

#### **Johns Hopkins Center for Health Security** [to 12 Apr 2025]

https://centerforhealthsecurity.org/newsroom Center News [Selected] No new digest content identified.

### MSF/Médecins Sans Frontières\_ [to 12 Apr 2025]

http://www.msf.org/ Latest [Selected Announcements] Myanmar

MSF steps up response in Myanmar following devastating earthquake

Project Update 10 Apr 2025

Conflict in Sudan

Stories of violence and forced displacement from South Kordofan, Sudan.

Voices from the Field 8 Apr 2025

Haiti

<u>Haiti: MSF withdraws from two medical facilities in Port-au-Prince as widespread violence</u> intensifies

Press Release 8 Apr 2025

### National Academy of Medicine - USA [to 12 Apr 2025]

https://nam.edu/programs/ News [Selected] Apr 10, 2025

#### New NAM Special Publication on the Use of Generative AI in Health and Medicine

WASHINGTON — While the integration of generative AI in health care holds significant potential to transform the practice of medicine and the health and well-being of patients, successful, ethical, and equitable implementation of generative AI requires careful consideration of the associated risks, says a new <u>special publication</u> from the National Academy of Medicine. Collaboration among health care providers, patients, policymakers, ethicists, and researchers, along with a cross-sector commitment to maximizing the benefit of generative AI while minimizing the risks, is important for navigating the complexities...

### National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 12 Apr 2025]

https://www.nationalacademies.org/newsroom

News

No new digest content identified.

https://www.path.org/media-center/

Newsroom [Selected]

# Africa's medicines regulation gains momentum with landmark Green Book listings

Statement

PATH applauds AUDA-NEPAD and AMRH on the launch of the AMRH Green Book, a significant step forward in strengthening Africa's regulatory systems. This <u>recently launched AMRH Green Book</u> is a publicly available resource that provides information on medicines scientifically evaluated for safety, efficacy, and quality and supports national marketing authorization decisions across African Union (AU) member states...

Published: April 2025

# PATH Kenya and partners launch Mother-Baby Friendly Initiative Plus

MBFI+ is a comprehensive care model to optimize feeding and save lives of SSNBs. This systems strengthening approach links kangaroo mother care, nurturing care, psychosocial support, specialized lactation support, locally appropriate human milk banking, and prevention and treatment of malnutrition as a packaged holistic intervention for mother and baby.

# **Sabin Vaccine Institute** [to 12 Apr 2025]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

**UNAIDS** [to 12 Apr 2025]

http://www.unaids.org/en News, Stories, Updates Feature Story

# <u>Impact of US funding cuts on the global AIDS response — Weekly update</u> 08 April 2025

... Across all countries that received significant US funding for their AIDS programmes, grassroots organizations and community health workers that provide services to vulnerable and marginalized people have been deeply affected by US funding cuts. Among 70 UNAIDS Country Offices that have submitted data on the situation, 40% reported that community-led services had been stopped by the US funding cuts. By comparison, 30% reported that services by international NGOs had been stopped, and 3% reported that government services had been stopped...

#### **UNICEF** [to 12 Apr 2025]

https://www.unicef.org/media/press-releases Latest press releases, news notes and statements [Seelected] Statement 07 April 2025

### **World must act with urgency to save Palestinians in Gaza**

NEW YORK, AMMAN, COPENHAGEN, GENEVA, ROME, 7 April 2025 - ", For over a month, no commercial or humanitarian supplies have entered Gaza. "More than 2.1 million people are trapped, bombed and starved again, while, at crossing points, food, medicine, fuel and shelter supplies are piling up, and vital equipment is s...

**Unitaid** [to 12 Apr 2025] https://unitaid.org/Featured News

#### News releases

# A unified response to a silent threat: tackling Chagas through integrated care 11 April 2025

# **Vaccine Equity Cooperative [nee Initiative]** [to 12 Apr 2025]

https://vaccineequitycooperative.org/news/

News

No new digest content identified.

# **Vaccination Acceptance & Demand Initiative [Sabin)** [to 12 Apr 2025]

https://www.vaccineacceptance.org/

News

No new digest content identified.

# Vaccine Confidence Project [to 12 Apr 2025]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

### Vaccine Education Center – Children's Hospital of Philadelphia [to 12 Apr 2025]

http://www.chop.edu/centers-programs/vaccine-education-center

News

No new digest content identified.

#### Wellcome Trust [to 12 Apr 2025]

https://wellcome.org/news/all News. Opinion, Reports No new digest content identified.

#### **The Wistar Institute** [to 12 Apr 2025]

https://www.wistar.org/news/press-releases

Press Releases

No new digest content identified.

### World Bank [to 12 Apr 2025]

http://www.worldbank.org/en/news/all

All News [Selected]

# **Historic Expansion in Social Protection in Past Decade**

Yet, three in four people in low-income countries still lack coverage WASHINGTON, April 7, 2025 – A new World Bank report reveals both the progress and the ongoing challenges in strengthening social... Date: April 07, 2025 Type: Press Release

### **Enabling Women's Access to Economic Opportunities in Fragile Settings**

KEY HIGHLIGHTS In fiscal year 2024, the World Bank committed nearly \$3 billion in International Development Association (IDA) funding and over \$1 billion in International Bank for Reconstruction and Development...

Date: April 07, 2025 Type: Result Brief

### WFPHA: World Federation of Public Health Associations [to 12 Apr 2025]

https://www.wfpha.org/ Blog, Events No new digest content identified.

### World Medical Association [WMA] [to 12 Apr 2025]

https://www.wma.net/news-press/press-releases/ Press Releases No new digest content identified.

# World Organisation for Animal Health [OIE] [to 12 Apr 2025]

https://www.oie.int/ Press Releases, Statements No new digest content identified.

::::::

#### **ARM [Alliance for Regenerative Medicine]** [to 12 Apr 2025]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

**BIO** [to 12 Apr 2025]

https://www.bio.org/press-releases

Press Releases

BIO Statement on National Security Commission on Emerging Biotechnology Report: The Need for Immediate & Bold Action to Secure the U.S. Position as the Global Leader in Biotechnology

WASHINGTON, DC, April 8, 2025 – Today, the National Security Commission on Emerging Biotechnology (NSCEB), a bipartisan legislative commission established by Congress, issued its much-anticipated report detailing how the United States risks losing its position as the global leader in biotechnology and what must be done to maintain and advance our lead in this critical field. In response, John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement...

# **DCVMN – Developing Country Vaccine Manufacturers Network** [to 12 Apr 2025]

http://www.dcvmn.org/ News; Upcoming events No new digest content identified.

# ICBA – International Council of Biotechnology Associations [to 12 Apr 2025]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

### **IFPMA** [to 12 Apr 2025]

https://ifpma.org/

News, Statements [Selected]

Statement 7 April 2025

# 13th Resumed meeting of the Intergovernmental Negotiating Body (INB)

By IFPMA

On 7 April in Geneva, IFPMA delivered a statement at the 13th resumed meeting of the INB to agree a WHO instrument for pandemic prevention, preparedness, and response.

# **International Alliance of Patients' Organizations – IAPO** [to 12 Apr 2025]

https://www.iapo.org.uk/news

Press and media [Selected]

No new digest announcements identified.

#### **International Generic and Biosimilar Medicines Association [IGBA]**

https://www.igbamedicines.org/

News

No new digest announcements identified.

#### **PhRMA** [to 12 Apr 2025]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

#### **AstraZeneca**

<u>Press Releases</u>

# <u>AstraZeneca showcases innovation in infectious disease protection at ESCMID Global 2025</u> <u>08 April 2025</u>

- :: Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
- :: Data include 20 years of real-world effectiveness for Fluenz/FluMist

#### **Bavarian Nordic**

Latest News - No new digest announcements identified.

### **Bharat Biotech**

<u>Press Releases</u> - No new digest announcements identified.

#### BioCubaFarma - Cuba

<u>Últimas Noticias</u> - No new digest announcements identified.

#### **Biological E**

<u>News</u> - No new digest announcements identified.

#### **BioNTech**

Press Releases - No new digest announcements identified.

# **Boehringer**

<u>Press Releases</u> - No new digest announcements identified.

#### **CanSinoBIO**

<u>News</u> - Website not responding at inquiry

#### **CIGB**

<u>Latest News</u> - No new digest announcements identified.

#### CinnaGen

Recent News - No new digest announcements identified.

### **Clover Biopharmaceuticals** – China

News - No new digest announcements identified.

#### Curevac

News - No new digest announcements identified.

# **Gamaleya National Center/Sputnik**

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] <u>https://sputnikvaccine.com/</u> - No new digest announcements identified [Last: 31 Aug 2022]

#### **GSK**

Press releases for media - No new digest announcements identified.

#### **EuBiologics**, S Korea

<u>News</u> - No new digest announcements identified.

#### IMBCAMS, China

Home - Website not responding at inquiry.

#### JNJ Innovative Medicine [Janssen]

<u>Press Releases</u> - No new digest announcements identified

#### Merck

News releases - No new digest announcements identified

#### Moderna

Press Releases

# Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

CAMBRIDGE, MA / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the European Society

of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Vienna, Austria, from April 11-15, 2025.

#### Nanogen

News - No new digest announcements identified.

#### **Novartis**

News - No new digest announcements identified on website.

# Novartis plans to invest \$23 billion in US sites as Trump renews drug tariff threats

By Patrick Wingrove

Reuters, April 11, 2025 2:22 PM EDT Updated a day ago

- Novartis plans to build and expand 10 U.S. facilities
- New facilities include six manufacturing plants and a research and development site
- The construction will take place over five years, create more than 4,000 jobs]

Swiss drugmaker Novartis said on Thursday it plans to spend \$23 billion to build and expand 10 facilities in the U.S., as it grapples with renewed threats of drug import duties from the Trump administration.

Novartis said it plans to build six new manufacturing plants, some of which will make raw pharmaceutical ingredients, as well as a new research and development site in San Diego, California...

#### **Novavax**

<u>Press Releases</u> Apr 10, 2025 Statement COVID-19

**Update on U.S. FDA BLA for Novavax's COVID-19 Vaccine** 

#### **Pfizer**

Recent Press Releases - No new digest announcements identified.

#### **R-Pharm**

https://rpharm-us.com/index.php [No news or media page identified]

#### Sanofi Pasteur

Press Releases - No new digest announcements identified.

#### **Serum Institute**

News & Announcements - No new digest announcements identified.

### Sinopharm/WIBPBIBP

News - No new digest announcements identified.

#### **Sinovac**

Press Releases - No new digest announcements identified.

#### **SK Biosciences**

<u>Press Releases</u> - No new digest announcements identified.

#### **Takeda**

<u>Newsroom</u> - No new digest announcements identified.

#### Valneva

Press Releases

April 9, 2025

<u>Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent</u> Shigella Vaccine Candidate S4V2

# **Vector State Research Centre of Viralogy and Biotechnology**

<u>Home</u> - [Website not responding [404 error]

#### WestVac Biopharma

Media - No new digest announcements identified.

# Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

#### Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: <a href="mailto:david.r.curry@centerforvaccineethicsandpolicy.org">david.r.curry@centerforvaccineethicsandpolicy.org</a>

# **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 1 <a href="https://www.tandfonline.com/toc/uabr21/current">https://www.tandfonline.com/toc/uabr21/current</a> [Reviewed earlier]

April 2025 Volume 27, Number 4: E237-301

https://journalofethics.ama-assn.org/issue/regret-moral-psychology-surgical-professionalism

# Issue Theme: Surgical Care of Incarcerated Patients

The United States incarcerates more people per capita than any other nation. Developing and maintaining clinically and ethically appropriate surgical care for incarcerees requires clinicians, health care organizations, and governments to actively resist historically entrenched patterns of devaluing incarcerees' humanity and personhood. Neglect of carceral patients' surgical care needs, in particular, remains systematized to the persistent detriment of incarcerees' perioperative and surgical care, recovery, outcomes, and overall health. Carceral surgical patients' risk/benefit profiles must be contextualized at every stage of their care by their diminished legal agency, restricted liberty, and increased environmental risk for a range of abuses and trauma. Carceral surgical patients' vulnerabilities can be exacerbated by uncertainty or conflict about the scope and applicability of state authority relative to clinicians' authority, which can manifest in fraught interactions among clinicians, law enforcement and security personnel, and carceral facility employees tasked with monitoring incarcerees outside carceral settings.

[Reviewed earlier]

#### **American Journal of Human Genetics**

Apr 03, 2025 Volume 112 Issue 4 p725-964

https://www.cell.com/ajhg/current

This month in The Journal

Alyson B. Barnes, Sara B. Cullinan

Genomic medicine has the potential to transform lives, but its integration into healthcare systems requires organization, coordination of regional and national efforts, and consistent funding. Moreover, the many different cultures and political structures, as well as health and health-care disparities, present around the world pose challenges to the adoption of a one-size-fits-all genomics program. Yet, the goals of improving health outcomes by meeting the specific needs of the community in a sustainable and equitable manner are shared by many national and international programs.

#### **American Journal of Infection Control**

April 2025 Volume 53 Issue 4 p415-536 <a href="http://www.ajicjournal.org/current">http://www.ajicjournal.org/current</a> [Reviewed earlier]

#### **American Journal of Preventive Medicine**

April 2025 Volume 68 Issue 4 p645-858 https://www.ajpmonline.org/current [Reviewed earlier]

#### **American Journal of Public Health**

April 2025 115(S1) http://ajph.aphapublications.org/toc/ajph/current [Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 4 (Apr 2025)

https://www.ajtmh.org/view/journals/tpmd/112/4/tpmd.112.issue-4.xml

#### **Annals of Internal Medicine**

March 2025 Volume 178, Issue 3 <a href="https://www.acpjournals.org/toc/aim/current">https://www.acpjournals.org/toc/aim/current</a> [Reviewed earlier]

# **Artificial Intelligence – An International Journal**

Volume 340 March 2025 <a href="https://www.sciencedirect.com/journal/artificial-intelligence/vol/340/suppl/C">https://www.sciencedirect.com/journal/artificial-intelligence/vol/340/suppl/C</a> [Reviewed earlier]

### **BMC Cost Effectiveness and Resource Allocation**

http://resource-allocation.biomedcentral.com/ (Accessed 12 Apr 2025) [No new digest content identified]

#### **BMC Health Services Research**

http://www.biomedcentral.com/bmchealthservres/content (Accessed 12 Apr 2025

### The cost of delivering COVID-19 vaccines in Mozambique: a bottom-up costing study

Vaccines were a key tool in controlling the COVID-19 pandemic. However, the cost of delivering these vaccines in low- and middle-income countries was highly uncertain, due to the unprecedented delivery volume ...

Authors: Tozé Namalela, Flavia Moi, Amélia Dipuve, Pedro Marizane Pota, José Guambe, Maria Tereza

Couto and Laura Boonstoppel

Citation: *BMC Health Services Research* 2025 25:521 Content type: Research Published on: 9 April 2025

# **BMC Infectious Diseases**

http://www.biomedcentral.com/bmcinfectdis/content

(Accessed 12 Apr 2025)

# Overcoming HPV vaccine hesitancy: insights from a successful school-based vaccination campaign in the Saa health district of Cameroon

Vaccination against human papillomavirus (HPV) represents a critical strategy in the global effort to eradicate cervical cancer. Nonetheless, the uptake of HPV vaccination in Cameroon has been slow, resulting ...

Authors: Eposi C. Haddison, Doris B. Engoung, Carole B. Bodo and Victor M. Njie

Citation: *BMC Infectious Diseases* 2025 25:465 Content type: Research Published on: 4 April 2025

# <u>Tackling infectious disease outbreak and vaccination misinformation: a community-based strategy in Niger State, Nigeria</u>

While studies might have found misinformation to affect health decision-making, it is not solely responsible; it also plays a role. The rapid spread of misinformation undermines public trust in health systems ...

Authors: Abara Erim, Sunday Oko, Sonia Biose, Kemisola Agbaoye, Okechi Eberechukwu Nzedibe,

Anwuli Nwankwo, Patrick Gimba and Vivianne Ihekweazu Citation: BMC Health Services Research 2025 25:513 Content type: Research Published on: 8 April 2025

#### **BMC Medical Ethics**

http://www.biomedcentral.com/bmcmedethics/content

(Accessed 12 Apr 2025)

The research relationship: participant perspectives on consent in biobanking

Authors: Rachel Thompson, Kate Lyle, Gabrielle Samuel, Jo Holliday, Fenella Starkey, Susan Wallace

and Anneke Lucassen

Content type: Research 12 April 2025

#### **BMC Medicine**

http://www.biomedcentral.com/bmcmed/content (Accessed 12 Apr 2025) [No new digest content identified]

### **BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 12 Apr 2025) [No new digest content identified]

#### **BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles (Accessed 12 Apr 2025)

# **Exploring influenza vaccination determinants through digital participatory surveillance**

Vaccination is key for mitigating the impact of recurring seasonal influenza epidemics. Despite the efficacy and safety of influenza vaccines, achieving optimal vaccination uptake remains a challenge. This stu...

Authors: Kathleen Kelley, Nicolò Gozzi, Mattia Mazzoli and Daniela Paolotti

Citation: BMC Public Health 2025 25:1345

Content type: Research Published on: 10 April 2025

# <u>Trusted health system implementation strategies to increase vaccination (TRUE SYNERGI):</u> a stepped-wedge cluster randomized trial to reduce HPV-related cancers

Despite the availability of highly effective HPV vaccines that can reduce HPV-associated cancer mortality, HPV vaccination rates in Texas rank 48th nationwide. Although evidence shows Latino parents are more a...

Authors: Daisy Y. Morales-Campos, Prajakta Adsul, Yuanyuan Liang, Erin Donovan, Leticia R.

Moczygemba and Jessica A. Kahn

Citation: BMC Public Health 2025 25:1331

Content type: Study Protocol Published on: 9 April 2025

### **BMC Research Notes**

http://www.biomedcentral.com/bmcresnotes/content (Accessed 12 Apr 2025)

[No new digest content identified]

#### **BMJ Evidence-Based Medicine**

April 2025 - Volume 30 - 2 https://ebm.bmj.com/content/30/2 [Reviewed earlier]

#### **BMJ Global Health**

April 2025 - Volume 10 - 4 https://gh.bmj.com/content/10/4 Analysis

<u>Transforming partnerships through transboundary research</u> (10 April, 2025) Alfredo Mayor, Lemu Golassa, Hamtandi Magloire Natama, Alberto L Garcia-Basteiro, Tacilta Nhampossa

# <u>Intersectional forces of urban inequality and the global HIV pandemic: a retrospective analysis</u> (9 April, 2025)

Ingrid T Katz, Dana Renee Thomson, Sindhu Ravishankar, Kennedy Otwombe, Erlyn Rachelle Macarayan, Carissa Novak, Alison R Schulte, Sidney Atwood, Liana Rosenkrantz Woskie, Zoe Siegel, Bruce D Agins, Janan Dietrich, Blair T Johnson, Erva-Jean Stevens, Lisa M Butler, Matthew Kavanagh

#### Original research

<u>Estimating the effects of interventions on increasing vaccination: systematic review and meta-analysis</u> (9 April, 2025)

Jiayan Liu, Yingli Zhang, Haochun Zhang, Hao Tan

#### **Practice**

Developing a framework for monitoring the stages towards achieving effective coverage and equity for maternal, newborn, child health and nutrition interventions (9 April, 2025) Patricia S Coffey, Megan E Parker, Katharine D Shelley, Elan Ebeling, Lydia Nguti, Sophia Knudson, Nesibu Agonafir, Sali Ahmed, Savitha Subramanian, Kimberly Mansen, Sadaf Khan, Cyril Engmann, Jessica C Shearer

#### **Bulletin of the World Health Organization**

2025 Mar 1; 103(3) <a href="https://www.who.int/publications/journals/bulletin/">https://www.who.int/publications/journals/bulletin/</a> [Reviewed earlier]

#### Cell

Apr 03, 2025 Volume 188 Issue 7 p1747-2042 https://www.cell.com/cell/current [Reviewed earlier]

# **Child Care, Health and Development**

Volume 51, Issue 2 March 2025 <a href="https://onlinelibrary.wiley.com/toc/13652214/current">https://onlinelibrary.wiley.com/toc/13652214/current</a> [Reviewed earlier]

# **Clinical Pharmacology & Therapeutics**

Volume 117, Issue 4 Pages: 859-1148 April 2025 <a href="https://ascpt.onlinelibrary.wiley.com/toc/15326535/current">https://ascpt.onlinelibrary.wiley.com/toc/15326535/current</a> [Reviewed earlier]

#### **Clinical Therapeutics**

April 2025 Volume 47 Issue 4 p249-336 http://www.clinicaltherapeutics.com/current [Reviewed earlier]

#### **Clinical Trials**

Volume 22 Issue 2, April 2025 https://journals.sagepub.com/toc/ctja/22/2 Research article Open access First published online October 15, 2024

# The state of individual participant data sharing for the highest-revenue medicines

Natansh D Modi https://orcid.org/0000-0003-3262-5374, Lee X Li, [...], and Ashley M Hopkins Amid growing emphasis from pharmaceutical companies, advocacy groups, and regulatory bodies for sharing of individual participant data, recent audits reveal limited sharing, particularly for high-revenue medicines. Therefore, this study aimed to assess the individual participant data-sharing eligibility of clinical trials supporting the Food and Drug Administration approval of the top 30 highest-revenue medicines for 2021.

Research article Restricted access

First published online December 29, 2024

<u>Consent to recontact for future research using linked primary healthcare data: Outcomes</u> and general practice perceptions from the ATHENA COVID-19 study

Kim Greaves kim.greaves@health.qld.gov.au, Amanda King https://orcid.org/0000-0002-6070-4582, [...], and Rosemary Korda+7

The ATHENA COVID-19 study was set up to recruit a cohort of patients with linked health information willing to be recontacted in future to participate in clinical trials and also to investigate the outcomes of people with COVID-19 in Queensland, Australia, using consent. This report describes how patients were recruited, their primary care data extracted, proportions consenting, outcomes of using the recontact method to recruit to a study, and experiences interacting with general practices requested to release the primary care data.

This report describes how primary care data were successfully extracted using consent, and that the majority of patients approached gave permission for their healthcare information to be used for research and be recontacted. The consent-to-recontact concept demonstrated its effectiveness to recruit to new research studies. The majority of general practices were willing to export identifiable patient healthcare data for linkage provided consent had been obtained.

#### **Conflict and Health**

http://www.conflictandhealth.com/ [Accessed 12 Apr 2025] [No new digest content identified]

# **Contemporary Clinical Trials**

Volume 151 April 2025

https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/151/suppl/C

[New issue; No digest content identified]

#### The CRISPR Journal

Volume 8, Issue 1 / February 2025 <a href="https://www.liebertpub.com/toc/crispr/8/1">https://www.liebertpub.com/toc/crispr/8/1</a> [Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025 <a href="https://link.springer.com/journal/40142/volumes-and-issues/13-1">https://link.springer.com/journal/40142/volumes-and-issues/13-1</a> [Reviewed earlier]

# **Current Medical Research and Opinion**

Volume 41, Issue 1 2025 <a href="https://www.tandfonline.com/toc/icmo20/current">https://www.tandfonline.com/toc/icmo20/current</a> [Reviewed earlier]

# **Current Opinion in Infectious Diseases**

April 2025 - Volume 38 - Issue 2 <a href="https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx">https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx</a> [Reviewed earlier]

#### **Current Protocols in Human Genetics**

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 12 Apr 2025] [No new digest content identified]

### **Developing World Bioethics**

Volume 25, Issue 1 Pages: 1-79 March 2025 <a href="https://onlinelibrary.wiley.com/toc/14718847/current">https://onlinelibrary.wiley.com/toc/14718847/current</a> [Reviewed earlier]

#### **Development in Practice**

Volume 34, Issue 6, 2024 https://www.tandfonline.com/toc/cdip20/34/6 [Reviewed earlier]

# **Development Policy Review**

Volume 43, Issue 3 May 2025 <a href="https://onlinelibrary.wiley.com/toc/14677679/current">https://onlinelibrary.wiley.com/toc/14677679/current</a> [New issue; No digest content identified]

# **Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-

New issue; No digest content identified

#### **Disasters**

Volume 49, Issue 3 July 2025 <a href="https://onlinelibrary.wiley.com/toc/14677717/current">https://onlinelibrary.wiley.com/toc/14677717/current</a> [New issue; No digest content identified]

#### **eBioMedicine**

Volume 114 In progress (April 2025) <a href="https://www.sciencedirect.com/journal/ebiomedicine/vol/113/suppl/C">https://www.sciencedirect.com/journal/ebiomedicine/vol/113/suppl/C</a> [Reviewed earlier]

# **EMBO Reports**

Volume 26 Issue 7 7 April 2025 https://www.embopress.org/toc/14693178/current *Editorial* 18 March 2025

#### **Under pressure**

Bernd Pulverer

Academic and federal institutions supporting research and healthcare in the USA face suffocating legislation and severe cutbacks, with dire knock-on effects on global research. How can the international scientific community buffer the impact.

Opinion 18 March 2025

#### NIH's 15% cap: a cost comparison and research outlook

Shina Caroline Lynn Kamerlin, Mikael H Elias

The decision by the US government to cap the NIH grant overhead rate to 15% will likely underfund the country's research institutions for their infrastructure relative to their international peers and the private sector. This move could jeopardize the country's lead in the biological sciences.

Science & Society 18 March 2025

<u>Decentralized databases in biomedical research: lessons from recent events: The recent shutdown of critical health databases by the US CDC is a wake-up call for the research community about the vulnerability of centralised databases</u>

Alfonso Valencia

Biological and medical databases are crucial resources without which biomedical research would come to a halt. However, centralized databases often face vulnerabilities, particularly when dependent on single institutions. In contrast, distributed databases enhance resilience, encourage international collaboration, and promote scientific advancement by supporting shared responsibility and improved accessibility.

#### **Emerging Infectious Diseases**

Volume 31, Number 4—April 2025 <a href="http://wwwnc.cdc.gov/eid/">http://wwwnc.cdc.gov/eid/</a> [New issue; No digest content identified]

## **Epidemics**

Volume 50 March 2025 <a href="https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C">https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C</a> [Reviewed earlier]

## **Epidemiology and Infection**

Volume 153 - 2025 <a href="https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue">https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue</a> [Reviewed earlier]

## **Ethics & Human Research**

Volume 47, Issue 1 Pages: 1-45 January–February 2025 <a href="https://onlinelibrary.wiley.com/toc/25782363/current">https://onlinelibrary.wiley.com/toc/25782363/current</a>

\*\*Moral distress in clinical research \*\*Research with incarcerated and homeless women [Reviewed earlier]

## **Ethics & International Affairs**

Volume 38 - Issue 4 - Winter 2024 <a href="https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue">https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue</a> [Reviewed earlier]

#### **Ethics, Medicine and Public Health**

Volume 32 2024 <a href="https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc">https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc</a> [Reviewed earlier]

## The European Journal of Public Health

Volume 35, Issue 1, February 2025 https://academic.oup.com/eurpub/issue/35/1 [Reviewed earlier]

# **Expert Review of Vaccines**

Volume 24, 2025 Issue 1 <a href="https://www.tandfonline.com/toc/ierv20/current">https://www.tandfonline.com/toc/ierv20/current</a> [Reviewed earlier]

## **Foreign Affairs**

January/February 2025 https://www.foreignaffairs.com/issues/2025/104/1 Special Section

## Will Trump Change the World?

## **Forum for Development Studies**

Volume 52, 2025 - Issue 1 http://www.tandfonline.com/toc/sfds20/current **Co-creating knowledge in development studies** 

[Reviewed earlier]

#### **Frontiers in Medicine**

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463 [Accessed 12 Apr 2025] [No new digest content identified]

#### **Gene Therapy - Nature**

Volume 32 Issue 2, March 2025 https://www.nature.com/gt/volumes/32/issues/2 [Reviewed earlier]

#### **Genetics in Medicines**

Volume 27, Issue 4 April 2025 <a href="https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/4">https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/4</a> Research article Abstract only

Genomic sequencing in diverse and underserved pediatric populations: Parent perspectives on understanding, uncertainty, psychosocial impact, and personal utility of results

Barbara B. Biesecker, Sara L. Ackerman, Kyle B. Brothers, Kelly M. East, ... Jessica Ezzell Hunter Article 101363

#### **Genome Medicine**

https://genomemedicine.biomedcentral.com/articles [Accessed 12 Apr 2025] [No new digest content identified]

## **Global Health Action**

Volume 18, Issue 1 (2025) <a href="https://www.tandfonline.com/toc/zgha20/current?nav=tocList">https://www.tandfonline.com/toc/zgha20/current?nav=tocList</a> [Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024 <a href="http://www.ghspjournal.org/content/current">http://www.ghspjournal.org/content/current</a> [Reviewed earlier]

https://www.loc.gov/collections/global-legal-monitor/ https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\_desc [Accessed 12 Apr 2025] [No new digest content identified]

#### **Global Public Health**

Volume 20, Issue 1 (2025) <a href="http://www.tandfonline.com/toc/rgph20/current">http://www.tandfonline.com/toc/rgph20/current</a> [Reviewed earlier]

#### **Globalization and Health**

http://www.globalizationandhealth.com/ [Accessed 12 Apr 2025] [No new digest content identified]

# **Health and Human Rights**

Volume 26, Issue 2, December 2024 https://www.hhrjournal.org/volume-26-issue-2-december-2024/ **Special Section: Distress Migration and the Right to Health** [Reviewed earlier]

# **Health Economics, Policy and Law**

Volume 19 - Issue 4 - October 2024 <a href="https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue">https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue</a> [Reviewed earlier]

## **Health Policy and Planning**

Volume 40, Issue 3, April 2025 https://academic.oup.com/heapol/issue/40/3 [Reviewed earlier]

#### **Health Research Policy and Systems**

http://www.health-policy-systems.com/content [Accessed 12 Apr 2025] [No new digest content identified]

## **Human Gene Therapy**

Volume 36, Issue 5-6 / March 2025 <a href="https://www.liebertpub.com/toc/hum/36/5-6">https://www.liebertpub.com/toc/hum/36/5-6</a> [Reviewed earlier]

#### **Humanitarian Practice Network**

https://odihpn.org/

## Featured Publications

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025

https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList

Selected Content

[Reviewed earlier]

### **Immunity**

Mar 11, 2025 Volume 58 Issue 3 p515-766 https://www.cell.com/immunity/current

[Reviewed earlier]

## **Infectious Agents and Cancer**

http://www.infectagentscancer.com/

[Accessed 12 Apr 2025]

[No new digest content identified]

## **Infectious Diseases of Poverty**

http://www.idpjournal.com/content

[Accessed 12 Apr 2025]

[No new digest content identified]

#### **International Health**

Volume 17, Issue 2, March 2025

https://academic.oup.com/inthealth/issue/17/2

[Reviewed earlier]

#### **International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024)

https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml

[Reviewed earlier]

## **International Journal of Community Medicine and Public Health**

Vol. 12 No. 4 (2025): April 2025

https://www.ijcmph.com/index.php/ijcmph/issue/view/123

[Reviewed earlier]

## **International Journal of Epidemiology**

Volume 54, Issue 1, February 2025

https://academic.oup.com/ije/issue/54/1

[Reviewed earlier]

## **International Journal of Human Rights in Healthcare**

Volume 18 Issue 1 2025

https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1

Table of contents [Reviewed earlier]

#### **JAMA**

April 8, 2025, Vol 333, No. 14, Pages 1187-1270 https://jamanetwork.com/journals/jama/currentissue Viewpoint

## How Should Health Care and Public Health Respond to the New US Administration?

Steven H. Woolf, MD, MPH

JAMA. 2025;333(14):1197-1198. doi:10.1001/jama.2025.1218

This Viewpoint discusses scientific, medical, and public health actions, including withdrawing from the World Health Organization, taken so far during the first week of the Trump administration.

... How do we know where to draw the line, and when it is time to resist? The touchstone must be science, the evidence from rigorous, published, peer-reviewed research. We must draw the line when the science is clear that a policy will increase the risk of disease, complications, or premature death.

For example, the science is clear that childhood vaccines save lives. Before vaccines, thousands of children died each year from infectious diseases such as poliomyelitis. In one of the greatest public health achievements of the 20th century, immunizing children virtually eradicated these diseases. Physicians now rarely encounter vaccine-preventable diseases, but they know from the science that outbreaks will return and claim lives again if the pediatric population loses herd immunity. The latter is likely if politicians sow doubt about vaccine safety, parents seek exemptions, and schools relax immunization requirements. The profession knows this would put children at risk and must firmly resist.

#### Editorial

#### Reaffirming the JAMA Network Commitment to the Health of Patients and the Public

Kirsten Bibbins-Domingo, PhD, MD, MAS; Robert O. Bonow, MD, MS; Neil M. Bressler, MD; Linda Brubaker, MD, MS; Dimitri Christakis, MD, MPH; Stacy L. Christiansen, MA; Gregory Curfman, MD; Mary L. (Nora) Disis, MD; Annette Flanagin, RN, MA; Sandro Galea, MD, DrPH; Sharon K. Inouye, MD, MPH; S. Andrew Josephson, MD; Melina R. Kibbe, MD; Tracy A. Lieu, MD, MPH; Preeti N. Malani, MD, MSJ; Mary M. McDermott, MD; Christopher C. Muth, MD; Dost Öngür, MD, PhD; Hannah Park; Jay F. Piccirillo, MD; Eli N. Perencevich, MD, MS; Roy H. Perlis, MD, MSc; Joseph S. Ross, MD; Kanade Shinkai, MD, PhD; Kristin L. Walter, MD, MS

#### **Toward a Unified Vision for US Biomedical Research**

E. Albert Reece, MD, PhD, MBA; Victor J. Dzau, MD JAMA. 2025;333(14):1199-1200. doi:10.1001/jama.2025.0893

This Viewpoint discusses the need for the US to foster public-private partnerships, advance convergence science, and prioritize workforce development in order to maintain its position as a global leader in biomedical research, particularly in the face of rising competition from countries around the world.

#### **Revising US MMR Vaccine Recommendations Amid Changing Domestic Risks**

Benjamin Rader, PhD, MPH; Rochelle P. Walensky, MD, MPH; Wesley S. Rogers, MD; et al. JAMA. 2025;333(14):1201-1202. doi:10.1001/jama.2025.3867

This Viewpoint discusses updating the existing recommendation for an additional early MMR dose to infants aged 6 to 11 months traveling to any region with increased probability of measles exposure.

#### JAMA Health Forum

April 2025, Vol 6, No. 4 <a href="https://jamanetwork.com/journals/jama-health-forum/issue">https://jamanetwork.com/journals/jama-health-forum/issue</a> [Reviewed earlier]

#### **JAMA Pediatrics**

April 2025, Vol 179, No. 4, Pages 359-482 <a href="https://jamanetwork.com/journals/jamapediatrics/currentissue">https://jamanetwork.com/journals/jamapediatrics/currentissue</a> [New issue; No digest content identified]

### **JBI Evidence Synthesis**

April 2025 - Volume 23 - Issue 4 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [New issue; No digest content identified]

### **Journal of Adolescent Health**

March 2025 Volume 76 Issue 3 p341-526 <a href="https://www.jahonline.org/current">https://www.jahonline.org/current</a> [Reviewed earlier]

# **Journal of Artificial Intelligence Research**

Vol. 82 (2025)
<a href="https://www.jair.org/index.php/jair">https://www.jair.org/index.php/jair</a>
Contents

[New issue; No digest content identified]

#### **Journal of Community Health**

Volume 50, Issue 2 April 2025

https://link.springer.com/journal/10900/volumes-and-issues/50-2

Original Paper 05 October 2024 Pages: 201 - 210

<u>Factors Associated with Parents' COVID-19 Vaccination Decisions for Their Children in an Economically Marginalized, Diverse Community</u>

Ben Rudolph, Sumit Sharma, Anna E. Price

# Vaccine Beliefs Among Uninsured People Receiving Care at Free Clinics

Caroline C. Liu, Julio A. Siliezar, Michael S. Wilkes

Original Paper Open access 22 October 2024 Pages: 270 - 279

#### **Journal of Current Medical Research and Opinion**

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

https://www.cmro.in/index.php/jcmro/issue/view/91

[Reviewed earlier]

# **Journal of Development Economics**

Volume 174 May 2025

https://www.sciencedirect.com/journal/journal-of-development-economics/vol/174/suppl/C [Reviewed earlier]

## **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024 <a href="http://journals.sagepub.com/toc/jre/current">http://journals.sagepub.com/toc/jre/current</a> [Reviewed earlier]

# **Journal of Epidemiology & Community Health**

March 2025 - Volume 79 - 3 https://jech.bmj.com/content/79/3 [Reviewed earlier]

#### **Journal of Evidence-Based Medicine**

Volume 18, Issue 1 March 2025 <a href="https://onlinelibrary.wiley.com/toc/17565391/current">https://onlinelibrary.wiley.com/toc/17565391/current</a> [Reviewed earlier]

#### **Journal of Global Ethics**

Volume 20, Issue 3 (2024)
<a href="http://www.tandfonline.com/toc/rjge20/current">http://www.tandfonline.com/toc/rjge20/current</a>
<a href="mailto:Special Issue: 20th Anniversary Forum">Special Issue: 20th Anniversary Forum</a>
<a href="mailto:Reviewed earlier">[Reviewed earlier</a>]

#### **Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 1, February 2025 <a href="https://muse.jhu.edu/issue/54278">https://muse.jhu.edu/issue/54278</a> *Table of Contents*[Reviewed earlier]

# **Journal of Immigrant and Minority Health**

Volume 27, Issue 1 February 2025 <a href="https://link.springer.com/journal/10903/volumes-and-issues/27-1">https://link.springer.com/journal/10903/volumes-and-issues/27-1</a> [Reviewed earlier]

## **Journal of Immigrant & Refugee Studies**

Volume 23, Issue 1 (2025) <a href="https://www.tandfonline.com/toc/wimm20/current">https://www.tandfonline.com/toc/wimm20/current</a> [Reviewed earlier]

# **Journal of International Development**

Volume 37, Issue 2 Pages: 1-619 March 2025 <a href="https://onlinelibrary.wiley.com/toc/10991328/current">https://onlinelibrary.wiley.com/toc/10991328/current</a> [Reviewed earlier]

#### **Journal of Medical Ethics**

April 2025 - Volume 51 - 4 http://jme.bmj.com/content/current [Reviewed earlier]

### **Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024) https://institutionalrepository.aah.org/jpcrr/ [Reviewed earlier]

## **The Journal of Pediatrics**

Volume 277 February 2025 <a href="https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C">https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C</a> [Reviewed earlier]

## **Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1 https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList RESEARCH ARTICLE Open Access

<u>Convergence of Product, Production, and Supply Chain Design Rules: Evidence From Pharmaceutical Pre-Competitive Collaboration Networks</u>

Jagjit Singh Srai, Tomás Seosamh Harrington, Nitin R. Joglekar, Sriram Narayanan

Pages: 314-334

First Published: 26 February 2025

Open Access

## **Evaluating quality reward and other interventions to mitigate US drug shortages**

Sergey Naumov, In Joon Noh, Hui Zhao

Pages: 335-372

First Published: 08 October 2024

**Highlights** 

- While the effectiveness of the two existing interventions (expediting drug approvals and nudging manufacturers to increase production) is limited by the willingness of other manufacturers to cooperate, the quality reward intervention can sustainably mitigate shortages by incentivizing manufacturers to invest in quality management, reducing disruptions and addressing a major underlying issue for shortages.
- In addition to price, our paper shows that drug buyers, such as GPOs, should take manufactures' quality management into consideration in their purchasing decisions because such reward effectively reduces shortages in the long term, which benefit buyers and patients.
- In implementing quality reward, we caution regulators and practitioners of the caveat of a potential monopolistic market dominated by one high-quality manufacturer, which we show can be

addressed by carefully designing a quality disclosure mechanism, such as reporting discrete quality types (vs. continuous quality scores).

# **Journal of Public Health Management & Practice**

March/April 2025 - Volume 31 - Issue 2 <a href="https://journals.lww.com/jphmp/pages/currenttoc.aspx">https://journals.lww.com/jphmp/pages/currenttoc.aspx</a> [Reviewed earlier]

# **Journal of Public Health Policy**

Volume 46, Issue 1 March 2025 <a href="https://link.springer.com/journal/41271/volumes-and-issues/46-1">https://link.springer.com/journal/41271/volumes-and-issues/46-1</a> [Reviewed earlier]

## **Journal of the Royal Society – Interface**

April 2025 Volume 22 Issue 225 <a href="https://royalsocietypublishing.org/toc/rsif/current">https://royalsocietypublishing.org/toc/rsif/current</a> [Reviewed earlier]

#### **Journal of Travel Medicine**

Volume 32, Issue 3, April 2025 https://academic.oup.com/jtm/issue [Reviewed earlier]

#### **Journal of Virology**

Volume 99 • Number 2 • February 2025 <a href="http://jvi.asm.org/content/current">http://jvi.asm.org/content/current</a> [Reviewed earlier]

#### **The Lancet**

Apr 12, 2025 Volume 405 Number 10486 p1203-1312 <a href="https://www.thelancet.com/journals/lancet/issue/current">https://www.thelancet.com/journals/lancet/issue/current</a> [New issue; No digest content identified]

#### The Lancet Child & Adolescent Health

Apr 2025 Volume 9 Number 4 p211-282, e10-e12 <a href="https://www.thelancet.com/journals/lanchi/issue/current">https://www.thelancet.com/journals/lanchi/issue/current</a> [Reviewed earlier]

## **Lancet Digital Health**

Apr 2025 Volume 7 Number 4 e232-e294 <a href="https://www.thelancet.com/journals/landig/issue/current">https://www.thelancet.com/journals/landig/issue/current</a> [Reviewed earlier]

#### **Lancet Global Health**

Apr 2025 Volume 13 Number 4 e599-e777 <a href="https://www.thelancet.com/journals/langlo/issue/current">https://www.thelancet.com/journals/langlo/issue/current</a> [Reviewed earlier]

#### **Lancet Infectious Diseases**

Apr 2025 Volume 25 Number 4 p357-470, e191-e254 <a href="https://www.thelancet.com/journals/laninf/issue/current">https://www.thelancet.com/journals/laninf/issue/current</a> [Reviewed earlier]

#### **Lancet Public Health**

Apr 2025 Volume 10 Number 4 e264-e346 <a href="https://www.thelancet.com/journals/lanpub/issue/current">https://www.thelancet.com/journals/lanpub/issue/current</a> [Reviewed earlier]

## **Lancet Respiratory Medicine**

Mar 2025 Volume 13 Number 3 p189-288, e17-e19 <a href="https://www.thelancet.com/journals/lanres/issue/current">https://www.thelancet.com/journals/lanres/issue/current</a> [Reviewed earlier]

#### **Maternal and Child Health Journal**

Volume 29, Issue 3 March 2025 <a href="https://link.springer.com/journal/10995/volumes-and-issues/29-3">https://link.springer.com/journal/10995/volumes-and-issues/29-3</a> [Reviewed earlier]

# **Medical Decision Making (MDM)**

Volume 45 Issue 3, April 2025 http://mdm.sagepub.com/content/current [Reviewed earlier]

#### The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 103, Issue 1 Pages: 1-241 March 2025 <a href="https://onlinelibrary.wiley.com/toc/14680009/current">https://onlinelibrary.wiley.com/toc/14680009/current</a> [Reviewed earlier]

## **Molecular Therapy**

Apr 02, 2025 Volume 33 Issue 4 p1305-1860 https://www.cell.com/molecular-therapy/current

#### In this issue

Sickle cell disease (SCD) and  $\beta$ -thalassemia are two of the most common  $\beta$ -hemoglobinopathies, genetic diseases that affect the  $\beta$ -globin chains of hemoglobin. A single mutation in  $\beta$ -globin gene (*HBB*) causes the characteristic dysfunctional hemoglobin protein in SCD, while over 300 mutations across HBB cause severe anemia and reduced  $\beta$ -globin levels in  $\beta$ -thalassemia. Homology-directed repair (HDR) is a promising approach to restore HBB expression. However, HDR can be

challenging because the insert cannot be homologous to the endogenous gene, and synonymous codon-optimized, intron-less sequences may be inadequate.

#### **Nature**

Volume 640 Issue 8058, 10 April 2025

https://www.nature.com/nature/volumes/640/issues/8058

Editorial 08 Apr 2025

## Asilomar conference took courage and foresight — today, inclusivity would also be crucial

The 50th anniversary of a landmark biosafety conference is an opportunity to ensure its spirit lives on in today's scientists... The Asilomar conference came about as a result of scientists taking responsibility, at an early stage, for the risks inherent in their work, and making an effort to think about regulations to minimize the harm that such work could cause. Today's researchers should draw inspiration from the organizers' courage and foresight, and build on Asilomar's foundations by making such events inclusive.

World View 08 Apr 2025

# <u>'Now is not the time for despair' — how scientists can take a stand against political</u> interference

Lessons from environmental and other social movements can help researchers to protect scientific integrity from attack.

Fernando Tormos-Aponte

## **Nature Biotechnology**

Volume 43 Issue 3, March 2025 https://www.nature.com/nbt/volumes/43/issues/3 [Reviewed earlier]

#### **Nature Communications**

https://www.nature.com/subjects/health-sciences/ncomms (Accessed 12 Apr 2025) [Reviewed earlier]

#### **Nature Genetics**

Volume 57 Issue 4, April 2025

https://www.nature.com/ng/volumes/57/issues/4

Correspondence 10 Mar 2025

## Equity, ethics and the promise of partnership in genomic medicine

Nicola L. Hawley, Satupaitea Viali

Comment 08 Apr 2025

## Mapping genetic diversity with the GenomeIndia project

The rich ethnolinguistic and sociocultural differences that exist in India offers a unique opportunity to study human diversity. With the whole genomes of 10,000 healthy and unrelated Indians from 83 populations, the GenomeIndia project captures the genetic diversity of one of the highly underrepresented populations in the global genomics landscape. Chandrika Bhattacharyya, Krithika Subramanian, Bratati Kahali

Research Briefing 01 Apr 2025

Collaborative genome-wide association analysis with cryptography

Modern genome-wide association study (GWAS) datasets are biobank scale and are distributed across isolated repositories, owing to privacy concerns and regulations. Secure federated GWAS leverages cryptographic tools to enable joint analysis of these siloed datasets, thereby enhancing a range of common analyses while providing formal guarantees of data privacy.

Perspective 17 Mar 2025

## The Farm Animal Genotype-Tissue Expression (FarmGTEx) Project

The FarmGTEx Project aims to understand genetic control of gene activity under diverse biological and environmental contexts in domestic animals, providing a foundation for improving animal precision breeding, adaptation and human health.

Lingzhao Fang, Jinyan Teng, Curtis P. Van Tassell

Letter Open Access 24 Feb 2025

### Secure and federated genome-wide association studies for biobank-scale datasets

SF-GWAS is a workflow for secure, federated genome-wide association studies, implementing accurate, privacy-preserving principal-component analysis, linear/logistic regression and linear mixed model methods for biobank-scale multisite analyses.

Hyunghoon Cho, David Froelicher, Bonnie Berger

#### **Nature Human Behaviour**

Volume 9 Issue 3, March 2025 <a href="https://www.nature.com/nathumbehav/volumes/9/issues/2">https://www.nature.com/nathumbehav/volumes/9/issues/2</a> [Reviewed earlier]

#### **Nature Medicine**

Volume 31 Issue 3, March 2025 https://www.nature.com/nm/volumes/31/issues/3 [Reviewed earlier]

#### **Nature Reviews Drug Discovery**

Volume 24 Issue 4, April 2025 https://www.nature.com/nrd/volumes/24/issues/4 [Reviewed earlier]

#### **Nature Reviews Genetics**

Volume 26 Issue 4, April 2025 <a href="https://www.nature.com/nrg/volumes/26/issues/4">https://www.nature.com/nrg/volumes/26/issues/4</a> [Reviewed earlier]

## **Nature Reviews Immunology**

Volume 25 Issue 4, April 2025 <a href="https://www.nature.com/nri/volumes/25/issues/4">https://www.nature.com/nri/volumes/25/issues/4</a> [Reviewed earlier]

# **New England Journal of Medicine**

Volume 392 No. 14 April 10, 2025

## https://www.nejm.org/toc/nejm/medical-journal

[New issue; No digest content identified]

#### **NEJM Evidence**

Volume 4 No. 4 April 2025

https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[New issue; No digest content identified]

#### njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 12 Apr 2025] [No new digest content identified]

#### **Pediatrics**

Volume 155, Issue 4 April 2025 https://publications.aap.org/pediatrics/issue/155/4 Advocacy Case Studies

Orchestrating a Successful Veto Campaign Against a Detrimental School Immunization Bill

Beth Bloom Emrick, MD; Elizabeth A. Copenhaver, MD; Jennifer Gerlach, MD; Jamie L. Jeffrey, MD; Andrea M. Lauffer, MD ...

Quality Reports

# <u>Improving Human Papillomavirus Vaccine Administration Using Medical-Dental Integration</u>

Jessica L. Jack, MD; Amy B. Stein, PhD; Laura J. Podewils, PhD; Kristin Breslin, MPH; Scott Hamilton, DDS ...

#### **PharmacoEconomics**

Volume 43, Issue 4 April 2025 https://link.springer.com/journal/40273/volumes-and-issues/43-3 [Reviewed earlier]

#### **PLoS Biology**

https://journals.plos.org/plosbiology/ (Accessed 12 Apr 2025)

## Priorities for rapid and cost-effective vaccines to improve outbreak responses

Sarah C. Gilbert

Perspective | published 07 Apr 2025 PLOS Biology https://doi.org/10.1371/journal.pbio.3003114

#### **PLoS Genetics**

https://journals.plos.org/plosgenetics/ (Accessed 12 Apr 2025) [No new digest content identified]

#### **PLoS Global Public Health**

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE NEWEST FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 12 Apr 2025)

# <u>Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination</u> schedules in Malawi

Catherine Wenger, Ernest O. Asare, Jiye Kwon, Xiao Li, Edson Mwinjiwa, Jobiba Chinkhumba, Khuzwayo C. Jere, Daniel Hungerford, Nigel A. Cunliffe, A. David Paltiel, Virginia E. Pitzer Research Article | published 10 Apr 2025 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0004341

# <u>Fighting tuberculosis hand in hand: A call to engage communities affected by TB as</u> essential partners in research

N. Venkatesan, L. Faust, R. Lobo, H. Enkh-Amgalan, T. Kunor, Z. Sifumba, S. Rane, K. O'Brien, B. Kumar, C.N. Maimbolwa, M. Mayta, H. Patel, L.M. Huong, P. Heitkamp, S. Huddart, K. Romanowski, M. Hiebert, A.J. Zimmer, E.L. MacLean, G. Caceres-Cardenas, L. Villa Castillo, J. Black, M. Batchu, C.A. Tschampl, E. Rea, T. Campbell, C. Heffernan, R. Long, L. Raithby, A. Daftary, Y. Chorna, A. Zheng, L. Martinez, S. Kulkarni, C.M. Denkinger, M.D.M. Castro, G. Sulis, J. Furin, L. McKenna, M. Frick, R.R. Nathavitharana, C. Oga-Omenka, R. Ananthakrishnan, J. Malar, C. Ugarte-Gil, W. Vandevelde, A.D. Kerkhoff, P. Winarni, G. Fox, T.A. Nguyen, A.K.J. Teo, H.M. Yapa, N.Y. Pham, A. Ratnasingham, S. Bernays, H.D. Trinh, U. Khan, G.G. Alvarez, A. Deluca, M. Nash, O. Rucsineanu, A. Vasiliu, J. Stillo, P. Nahid, M. Pai, J. Johnston, A.D. Harries, J.E. Golub Essay | published 09 Apr 2025 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0004437

# A qualitative study on behavioral and social drivers of COVID-19 vaccine amongst refugees and migrants in Pakistan

Zahra Ali Padhani, Maryam Hameed Khan, Rahima Yasin, Abdu R. Rahman, Sohail Lakhani, Mushtaq Mirani, Muhammad Khan Jamali, Zahid Ali Khan, Sana Khatoon, Riya Partab, Atta ul Haq, Vinay Kampalath, Seyed-Moeen Hosseinalipour, Karl Blanchet, Jai K. Das Research Article | published 08 Apr 2025 PLOS Global Public Health <a href="https://doi.org/10.1371/journal.pgph.0004444">https://doi.org/10.1371/journal.pgph.0004444</a>

#### Protecting global health partnerships in the era of destructive nationalism

Maya Adam, Desiree LaBeaud, Nokwanele Mbewu, Jennifer Gates, Randall Waechter, Mercy J. Borbor-Cordova, Lydiah Kibe, Sonia Alvarez, Annie Dori, Anil S. Bilimale, Meggie Mwoka, Jessica Deffler, Michele Spring, Avriel R. Diaz, Rachael Farquhar, Willy Dunbar, Comfort R. Phiri, Valerie A. Luzadis, Nicole Redvers, Cristina Alonso, Rosemary Rochford, Rachel Lowe, Kareem Coomansingh, Moses Laman, Rebeca Sultana, Sadie Ryan, Amaya L. Bustinduy, Anita S. Hargrave-Bouagnon, Shazia N. Ruybal-Pesántez, Zebedee Kerry, Trevor Kelebi, Samuel McEwen, Leanne Robinson, Maritza Salazar Campo, Till Bärnighausen

Opinion | published 08 Apr 2025 PLOS Global Public Health <a href="https://doi.org/10.1371/journal.pgph.0004428">https://doi.org/10.1371/journal.pgph.0004428</a>

Long-standing global partnerships, critical for protecting the health of human beings and the planet we share, are under attack in 2025. Around the world, a pendulum swing towards nationalism and populism [1] has threatened to destroy international scientific collaborations that took decades to build. Globally, the rise of hard-right extremism jeopardizes fragile structures established to protect the health and human rights of people everywhere [2]. The chaos of haphazard disruption, devoid of accountability, normalizes a lack of perceived responsibility for our fellow human beings [3]. Reckless

global socio-political shifts hurt all of us, as citizens of one world, sharing its limited resources and facing common threats of diseases that respect neither borders nor executive orders [4,5].

As scientists and global health advocates, we have dedicated our careers (and much of our lives) to developing and testing innovative solutions that anticipate, prevent, manage and eliminate serious threats to the health of our global community. Our new reality drives us to continue our work. We are accustomed to challenges and recognize their capacity to strengthen our vision for the future. We have learned important lessons, over decades of combined experience and we have joined forces, across the globe, to communicate these broadly [6]. We believe that long-term, trusting, resilient global partnerships have the potential to carry our global community through crises. If the global health community is to weather the current storm, we must rebuild, restore and reinforce our critically important bridges of collaboration, by tethering them to a set of solid, tested foundations [6] ...

## In danger: HIV vaccine research and development in Europe

Roger Tatoud, Yves Lévy, Roger Le Grand, Jose Alcami, Giorgio Barbareschi, Christian Brander, Andrea Cara, Behazine Combadière, François Dabis, Sarah Fidler, Tomáš Hanke, Carolina Herrera, Gunilla B. Karlsson Hedestam, Hester Kuipers, Sheena McCormack, Christiane Moog, Giuseppe Pantaleo, Laura Richert, Rogier W. Sanders, Robin Shattock, Hendrik Streeck, Rodolphe Thiebaut, Alexandra Trkola, Klaus Üeberla, Marit J. Van Gills, Ralf Wagner, Winfried Weissenhorn, Yazdan Yazdanpanah, Gabriella Scarlatti, Jean Daniel Lelièvre

Essay | published 08 Apr 2025 PLOS Global Public Health <a href="https://doi.org/10.1371/journal.pgph.0004364">https://doi.org/10.1371/journal.pgph.0004364</a>

#### **PLoS Medicine**

https://journals.plos.org/plosmedicine/ (Accessed 12 Apr 2025) [No new digest content identified]

#### **PLoS Neglected Tropical Diseases**

http://www.plosntds.org/ (Accessed 12 Apr 2025) [No new digest content identified]

#### **PLoS One**

http://www.plosone.org/ [Accessed 12 Apr 2025] [No new digest content identified]

# **PLoS Pathogens**

http://journals.plos.org/plospathoge ns/ [Accessed 12 Apr 2025] [No new digest content identified]

## PNAS - Proceedings of the National Academy of Sciences of the United States

April 15, 2025 | vol. 122 | no. 15 https://www.pnas.org/toc/pnas/122/15 Opinion April 9, 2025

The importance of playing the long game when it comes to pandemic surveillance

Freya M. Shearer and Marc Lipsitch

The COVID-19 pandemic highlighted the importance of gathering information on pathogen characteristics as early as possible when an outbreak strikes. But it also underscored how quickly much of that information becomes out-of-date as the virus and host populations change, weakening epidemiological analyses based on the early information and so the evidence for policy decisions. To prepare for future pandemics, more funds and scientific effort must be directed at ways to track these ongoing changes and regularly update estimates of pathogen characteristics.

#### **PNAS Nexus**

Volume 4, Issue 3, March 2025 https://academic.oup.com/pnasnexus/issue/4/3 [Reviewed earlier]

## **Prehospital & Disaster Medicine**

Volume 40 - Issue 1 - February 2025 <a href="https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue">https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue</a> [Reviewed earlier]

#### **Preventive Medicine**

Volume 192 March 2025 <a href="https://www.sciencedirect.com/journal/preventive-medicine/vol/192/suppl/C">https://www.sciencedirect.com/journal/preventive-medicine/vol/192/suppl/C</a> [Reviewed earlier]

# **Proceedings of the Royal Society B**

April 2025 Volume 292 Issue 2044 <a href="https://royalsocietypublishing.org/toc/rspb/current">https://royalsocietypublishing.org/toc/rspb/current</a> [New issue; No digest content identified]

#### **Public Health**

Volume 240 Pages 1-222 (March 2025) <a href="https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C">https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C</a> [Reviewed earlier]

#### **Public Health Ethics**

Volume 18, Issue 1, April 2025 http://phe.oxfordjournals.org/content/current [New issue; No digest content identified]

#### **Public Health Genomics**

2025, Vol. 28, No. 1 https://karger.com/phg/issue/28/1 [Reviewed earlier]

# **Public Health Reports**

Volume 140 Issue 1, January/February 2025 <a href="https://journals.sagepub.com/toc/phrg/140/1">https://journals.sagepub.com/toc/phrg/140/1</a> [Reviewed earlier]

### **Qualitative Health Research**

Volume 35 Issue 3, March 2025 <a href="https://journals.sagepub.com/toc/QHR/current">https://journals.sagepub.com/toc/QHR/current</a> [Reviewed earlier]

#### **Research Ethics**

Volume 21 Issue 1, January 2025 <a href="http://journals.sagepub.com/toc/reab/current">http://journals.sagepub.com/toc/reab/current</a> [Reviewed earlier]

## **Reproductive Health**

http://www.reproductive-health-journal.com/content [Accessed 12 Apr 2025] [No new digest content identified]

# Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles 11 Apr 2025

AI's ongoing impact: Implications of AI's effects on health equity for women's healthcare providers

Special report | English |

11 Apr 2025

<u>Critical factors for institutionalizing evidence-informed decision-making in healthcare organizations</u>

Review | Portuguese |

11 Apr 2025

Political support and micro-planning as success factors in a high-quality follow-up vaccination campaign in Ecuador, 2023

Special report | Spanish |

11 Apr 2025

<u>Vaccine-associated poliomyelitis: safety of the oral poliovirus vaccine, Brazil, 2013–2023</u>
Original research | Portuguese |

11 Apr 2025

<u>Integrated serological surveillance of communicable diseases in the Paraguayan Chaco, 2019</u>

Original research | English |

# **Risk Analysis**

Volume 45, Issue 3 Pages: 473-721 March 2025 <a href="https://onlinelibrary.wiley.com/toc/15396924/current">https://onlinelibrary.wiley.com/toc/15396924/current</a> [Reviewed earlier]

## **Risk Management and Healthcare Policy**

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 12 Apr 2025] [No new digest content identified]

# **Royal Society Open Science**

April 2025 Volume 12 Issue 4 https://royalsocietypublishing.org/toc/rsos/current [Reviewed earlier]

#### **Science**

Volume 388| Issue 6743| 11 Apr 2025 https://www.science.org/toc/science/current Editorial

## AI drug development's data problem

BY. Richard Gold, Robert Cook-Deegan

10 Apr 2025: 131

The future of drug discovery may be artificial intelligence (AI), but its present is not. AI is in its infancy in the field. To help AI mature, developers need nonproprietary, open, large, high-quality datasets to train and validate models, managed by independent organizations...

# **Science and Engineering Ethics**

Volume 31, Issue 2 April 2025 <a href="https://link.springer.com/journal/11948/volumes-and-issues/31-2">https://link.springer.com/journal/11948/volumes-and-issues/31-2</a> [Reviewed earlier]

#### **Science Translational Medicine**

Volume 17| Issue 793| 9 Apr 2025 https://www.science.org/toc/stm/current [New issue; No digest content identified]

#### **Scientific Reports**

https://www.nature.com/srep/articles?type=article [Accessed 12 Apr 2025] [No new digest content identified]

### **Social Science & Medicine**

Volume 370 April 2025

https://www.sciencedirect.com/journal/social-science-and-medicine/vol/370/suppl/C

[Reviewed earlier]

# **Systematic Reviews**

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 12 Apr 2025] [No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 46, Issue 2 April 2025 <a href="https://link.springer.com/journal/11017/volumes-and-issues/46-2">https://link.springer.com/journal/11017/volumes-and-issues/46-2</a> [Reviewed earlier]

#### **Travel Medicine and Infectious Diseases**

Volume 64 March—April 2025 <a href="https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/64/suppl/C">https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/64/suppl/C</a> [Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 30, Issue 3 Pages: i-iv, 143-230 March 2025 <a href="https://onlinelibrary.wiley.com/toc/13653156/current">https://onlinelibrary.wiley.com/toc/13653156/current</a> [Reviewed earlier]

#### **Vaccine**

Volume 52 11 April 2025 <a href="https://www.sciencedirect.com/journal/vaccine/vol/52/suppl/C">https://www.sciencedirect.com/journal/vaccine/vol/52/suppl/C</a> [Reviewed earlier]

#### **Vaccines**

https://www.mdpi.com/journal/vaccines

[Accessed 12 Apr 2025]

Open Access Systematic Review

<u>Strategies, Barriers, and Facilitators for Healthcare Professionals to Recommend HPV</u>
Vaccination: A Systematic Review

by Yihan Fu, Yinqi He, Zhitao Wang and Jing Sun

Vaccines 2025, 13(4), 402; https://doi.org/10.3390/vaccines13040402 (registering DOI) - 12 Apr 2025 *Abstract* 

Background/Objectives: The HPV vaccine has demonstrated efficacy in preventing approximately 90% of HPV infection-associated cancers. However, the global HPV vaccination coverage rate remains low. Healthcare professionals are trusted sources of information on vaccination. Enhancing their capacities to deliver credible information through appropriate [...]

#### Open Access Article

#### **Global Status of Adult Immunization Post COVID-19 Pandemic**

by Alba Vilajeliu, Victor Vega, Randie Gibson, Francisco Nogareda, Xiaojun Wang, Donald J. Brooks, Charles Shey Wiysonge, Osman Niyazi Cakmak, Osama Mere, Melanie Marti, Phillip Lambach, Stephanie Shendale, Marcela Contreras, Emmanuel Njambe, Erin Grace Sparrow, Joachim Hombach and Ann Lindstrand

Vaccines 2025, 13(4), 401; <a href="https://doi.org/10.3390/vaccines13040401">https://doi.org/10.3390/vaccines13040401</a> - 11 Apr 2025

Abstract

Background/Objective: Historically, immunization programs have focused on infants, children, and women of reproductive age. COVID-19 vaccination prompted countries to vaccinate adults. The objective of this manuscript is to provide a global overview of adult immunization policies post COVID-19 pandemic. Methods: We summarized WHO [...]

#### Value in Health

April 2025 Volume 28 Issue 4 p489-670 <a href="https://www.valueinhealthjournal.com/current">https://www.valueinhealthjournal.com/current</a> [Reviewed earlier]

# **World Development**

Volume 188 April 2025 <a href="https://www.sciencedirect.com/journal/world-development/vol/188/suppl/C">https://www.sciencedirect.com/journal/world-development/vol/188/suppl/C</a> [Reviewed earlier]

::::::

## Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

## **Pre-Print Servers**

#### arxiv

https://arxiv.org/

[Accessed 12 Apr 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2504.07432 [pdf, html, other]

<u>A model for cholera with infectiousness of deceased individuals and vaccination</u>

Abdramane Annour Saad, Julien Arino, Patrick M Tchepmo Djomegni, Mahamat S Daoussa Haggar

<u>arXiv:2504.03489</u> (cross-list from physics.soc-ph) [pdf, html, other]

**The Vaccination Game on Networks** 

Kausutua Tjikundi, Mark Broom

Vaccinations are an important tool in the prevention of disease. Vaccinations are generally voluntary for each member of a population and vaccination decisions are influenced by individual risk perceptions and contact structures within populations. In this study, we model vaccination uptake as an evolutionary game where individuals weigh perceived morbidity risks from both vaccination and infection. We incorporate epidemiological dynamics using an SIR model structured on networks, allowing us to determine the evolutionarily stable vaccination level for any given network topology. Our

analysis shows that vaccination coverage varies across networks depending on their structure and the relative cost of vaccination (the ratio of vaccine morbidity risk to infection morbidity risk). As this cost increases, vaccination uptake decreases universally, leading to a dominant non-vaccinator strategy when the cost is high. We find that networks with low to moderate degree variability have a relatively low evolutionarily stable vaccination level when this cost is low, as in such populations lower vaccination levels are necessary to achieve equivalent levels of disease prevalence to more heterogeneous networks with high degree variability, which thus show higher vaccination levels at lower relative costs. However, for heterogeneous networks, vaccination levels decline faster as costs rise, eventually falling below the level for the more homogeneous networks. Our findings align with previous studies on vaccination thresholds in structured populations and highlight how network heterogeneity influences vaccination dynamics.

### **Gates Open Research**

https://gatesopenresearch.org/browse/articles [Accessed 12 Apr 2025] [No new digest content identified]

#### medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 12 Apr 2025] [Filter: All articles]

<u>Towards the elimination of mother-to-child transmission of syphilis in the WHO European region: Implications from a survey in the non-European Union and European Economic Area countries</u>

Machiko Otani, Jane Rowley, Giorgi Kuchukhidze, Viatcheslav Grankov, Stela Bivol, On behalf of WHO EURO non-EU/EEA STI Surveillance network

medRxiv 2025.04.09.25325528; doi: https://doi.org/10.1101/2025.04.09.25325528

# <u>Conversational Artificial Intelligence for Translational Precision Medicine: Integrating Social Determinants of Health, Genomics, and Clinical Data with AI-HOPE-PM</u>

Ei-Wen Yang, Brigette Waldrup, Enrique Velazguez-Villarreal

medRxiv 2025.03.28.25324864; doi: https://doi.org/10.1101/2025.03.28.25324864 Revision

#### **Detection of Measles in Texas Wastewater**

Katherine M. Joseph, Xingwen Chen, Dhvani Parikh, Janelle Rios, Catherine L. Troisi, Michael J. Tisza, Anthony W. Maresso, Blake M. Hanson, Anna Gitter, Jennifer Deegan, Cici X. Bauer, John E. Balliew, Kristina D. Mena, Eric Boerwinkle, Fuqing Wu

medRxiv 2025.04.08.25325475; doi: https://doi.org/10.1101/2025.04.08.25325475

# The impact of COVID-19 on the implementation of routine immunisation for children in Rwanda

Edward Mbonigaba, Fengyun Yu, Mark Donald C. Reñosa, Frederick Nchang Cho, Qiushi Chen, Wenjin Chen, Claudia M. Denkinger, Shannon A. McMahon, Simiao Chen

medRxiv 2025.04.09.25325536; doi: https://doi.org/10.1101/2025.04.09.25325536

## **OSF Pre-prints**

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[Website not responding at inquiry]

# **Wellcome Open Research**

https://wellcomeopenresearch.org/browse/articles [Accessed 12 Apr 2025] [No new digest content identified]

\* \* \* \*

# Think Tanks

**Brookings** [to 12 Apr 2025] http://www.brookings.edu/ Reports, Events No new digest content identified.

# **Center for Global Development** [to 12 Apr 2025]

https://www.cgd ev.org/ All Research No new digest content identified.

## **Chatham House** [to 12 Apr 2025]

https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

# **Council on Foreign Relations** [to 12 Apr 2025]

https://www.cfr.org/media/news-releases New Releases [Selected] No new digest content identified.

CSIS [to 12 Apr 2025]
https://www.csis.org/
Reports [Selected]
No new digest content identified.

# **Kaiser Family Foundation** [to 12 Apr 2025]

https://www.kff.org/search/?post\_type=press-release Newsroom No new digest content identified.

## McKinsey Global Institute [to 12 Apr 2025]

https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

# **ODI** [Overseas Development Institute] [to 12 Apr 2025]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

### **Pew Research Center** [to 12 Apr 2025]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 12 Apr 2025] https://www.rand.org/pubs.html Published Research [Selected] Research Apr 8, 2025

## **Emerging Technology and Risk Analysis: Digital Personhood**

This report describes the implications of various forms of digital personhood: digital proof of the existence of a physical human, digital twins that provide virtual models of physical objects (i.e., a human), and virtual (or synthetic) persons.

**Urban Institute** [to 12 Apr 2025] https://www.urban.org/publications

New Research Publications - Selected

Brief

# Nonprofit Leaders' Top Concerns Entering 2025: An Analysis from the Nonprofit Trends and Impacts Study

April 9, 2025

Entering 2025, nonprofit leaders were most concerned about the intersecting challenges of financial instability owing to uncertain revenues and rising expenses, increasing program demand, and supporting their workforces amid these changes. This brief analyzes an open-ended survey response from late 2024 which asked nonprofit leaders about their primary concerns for their organizations in 2025. Nonprofit leaders highlighted concerns about sustainability, balancing increased demand with decreased funding, and vulnerability in a shifting funding landscape—all of which points to a prevailing sense of uncertainty among organizational leaders.

## **World Economic Forum** [to 12 Apr 2025]

https://agenda.weforum.org/press/ Media [Selected] No new digest content identified.

::::::

Public Consultations/Call for Inputs/Call for Papers

# <u>ICH - M11 EWG CLINICAL ELECTRONIC STRUCTURED HARMONISED PROTOCOL</u> (CESHARP)

This topic was endorsed by the ICH Management Committee in November 2018. This new guideline is proposed to provide comprehensive clinical protocol organisation with standardised content, with:

- A Template which presents the format and structure of the protocol, including the table of contents, common headers, and contents;
- A Technical Specification which presents the conformance, cardinality, and other technical attributes that enable the interoperable electronic exchange of protocol content.

The Technical Specification document and Template had reached Step 2b on 27 September 2022 and entered public consultation. They have been updated by the M11 EWG following the comments received. The Technical Specification is now being submitted for a second round of public consultations, and the Template is provided as a support to the consultation.

Rapporteur: Dr. Ronald Fitzmartin (FDA, United States)

Regulatory Chair: Dr. Noemie Manent (EC, Europe)

Date of Step 2b: 13 March 2025 Status: Step 3

Public consultation dates:

EC, Europe - Deadline for comments by 22 April 2025 HSA, Singapore - Deadline for comments by 25 April 2025 MHLW/PMDA, Japan - Deadline for comments by 1 May 2025 NMPA, China - Deadline for comments by 28 April 2025 SFDA, Saudi Arabia - Deadline for comments by 21 April 2025 TFDA, Chinese Taipei - Deadline for comments by 25 April 2025

\* \* \* \*

#### Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

......

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization,

products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.